Note: Descriptions are shown in the official language in which they were submitted.
CA 03089722 2020-07-27
1
DESCRIPTION
BISPECIFIC ANTIBODY
Technical Field
[0001]
The present invention relates to a bispecific antibody capable of specifically
binding
to PD-1 and CD3 respectively (hereinafter, which is abbreviated as a "PD-1/CD3
bispecific
antibody"), and a pharmaceutical composition containing the same as an active
ingredient, as
- 10 well as pharmaceutical therapeutic use thereof.
Background Art
[0002]
PD-1 is an immunosuppressive receptor belonging to an immunoglobulin family
and
is a molecule having a function of suppressing the immune activation signals
of T-cells
activated by stimulation through an antigen receptor. From analysis of PD-1
knock-out mice
or the like, it is known that PD-1 signals play important roles in suppression
of autoimmune
diseases such as autoimmune dilated cardiomyopathy, lupus-like syndrome,
autoimmune
encephalomyelitis, systemic lupus erythematosus, graft-versus-host disease,
type I diabetes
mellitus, and rheumatoid arthritis. Accordingly, it is pointed out that an
agent enhancing the
PD-1 signal could be a prophylactic or therapeutic agent for autoimmune
diseases.
[0003]
Bispecific antibodies recognizing PD-1 have been known as an agent enhancing a
PD-1 signal (Patent references 1 to 3) before. The bispecific antibodies are
composed of an
antigen-recognition site of an antibody recognizing CD3 that is a member of a
T-cell receptor
complex, and an antigen-recognition site of an antibody recognizing PD-1
linked to each
other using genetic engineering. The bispecific antibodies have an action of
enhancing the
inhibitory signal of PD-1 against the T-cell receptor complex by increasing
the frequency of
bringing PD-1 to the vicinity of the T-cell receptor complex. Furthermore, the
Patent
Literatures also state that PD-1 bispecific antibodies can be used for
prophylaxis or therapy of
autoimmune diseases.
[0004]
Incidentally, in protein formulation, expression of adverse reactions called
infusion
CA 03089722 2020-07-27
kr
2
reaction or cytokine release syndrome immediately after administration have
been concerned.
Formulations in which such reactions are reduced or suppressed have been
demanded.
[0005]
In the PD-1/CD3 bispecific antibody of the present invention, cytokine
production
stimulation after administration, which is considered to be a cause of the
above-mentioned
adverse reactions, is sufficiently reduced. Therefore, the PD-1/CD3 bispecific
antibody is
expected to be a pharmaceutical in which expression of the concerned adverse
reaction is
suppressed.
[0006]
Bispecific antibodies having such characteristics have not been reported to
date.
Citation List
Patent References
[0007]
Patent Reference 1: International Publication No. W02003/011911
Patent Reference 2: International Publication No. W02004/072286
Patent Reference 3: International Publication No. W02013/022091
Summary of Invention
Technical Problem
[0008]
The object of the present invention is to provide a new pharmaceutical agent
for
preventing, suppressing symptom progression or recurrence of or treating
autoimmune
diseases and the like.
Solution to Problem
[0009]
The present inventors have diligently studied and have focused on the PD-1/CD3
bispecific antibody of the present invention as an agent capable of solving
the
above-mentioned problem. The present inventors further have verified that the
PD-1/CD3
bispecific antibody could be an agent in which expression of reactions called
infusion reaction
or cytokine release syndrome is reduced, and have completed the present
invention.
[0010]
CA 03089722 2020-07-27
3
Furthermore, the inventors of the present invention have found that the PD-
1/CD3
bispecific antibody has characteristics of allowing interaction between the PD-
1 and PD-Li as
its ligand, and found that such characteristics contribute to enhancing or
sustaining of the
effect of the PD-1/CD3 bispecific antibody.
[0011]
That is, the present invention relates to the followings.
[1] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein the first arm specifically binding to PD-1 contains any one of VH
selected from:
(A) a heavy chain variable region (hereinafter, the "heavy chain variable
region" may be
abbreviated as "VH") having
(a) a complementary determining region 1 of the heavy chain variable region
(hereinafter,
the "complementary determining region 1 of the heavy chain variable region"
may be
abbreviated as "VH-CDR1") comprising an amino acid sequence set forth in SEQ
ID No. 6;
(b) a complementary determining region 2 of the heavy chain variable region
(hereinafter,
the "complementary determining region 2 of the heavy chain variable region"
may be
abbreviated as "VH-CDR2") comprising an amino acid sequence set forth in SEQ
ID No. 7;
and
(c) a complementary determining region 3 of the heavy chain variable region
(hereinafter,
the "complementary determining region 3 of the heavy chain variable region"
may be
abbreviated as "VH-CDR3") comprising an amino acid sequence set forth in SEQ
ID No. 8;
(B) a VH having
(a) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID No. 9;
(b) a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID No. 10;
and
(c) a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID No. 11;
(C) a VH having
(a) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID No. 12;
(b) a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID No. 13,
and
(c) a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID No. 14;
.. (D) a VH having
(a) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID No. 15;
(b) a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID No. 16;
and
(c) a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID No. 17;
and
CA 03089722 2020-07-27
sl
4
(E) a VH having
(a) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID No. 18;
(b) a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID No. 19;
and
(c) a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID No. 20;
and
wherein the second arm specifically binding to CD3 contains a VH having
(a) a VH-CDR1 comprising an amino acid sequence set forth in SEQ ID No.37;
(b) a VH-CDR2 comprising an amino acid sequence set forth in SEQ ID No.38; and
(c) a VH-CDR3 comprising an amino acid sequence set forth in SEQ ID No.39.
[2] The PD-1/CD3 bispecific antibody or antibody fragment thereof according to
the
preceding item [1], wherein one to five arbitrary amino acid residue(s) may be
respectively
substituted with other amino acid(s) (preferably, conservative amino acid(s)
thereof) in any
one or more of VH-CDR(s) selected from the VH-CDR1, VH-CDR2 and VH-CDR3 in the
first arm specifically binding to PD-1; and/or one to five arbitrary amino
acid residue(s) may
be respectively substituted with other amino acid(s) (preferably, conservative
amino acid(s)
thereof) in any one or more of VH-CDR(s) selected from the VH-CDR1, VH-CDR2
and
VH-CDR3 in the second arm specifically binding to CD3.
[3] The PD-1/CD3 bispecific antibody or antibody fragment thereof according to
the
preceding item [1] or [2], wherein
(i) the VH of the first arm specifically binding to PD-1 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 6,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 7,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 8;
and
(ii) the VH of the second arm specifically binding to CD3 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37,
(b) the VII-CDR2 comprising the amino acid sequence set forth in SEQ ID No.
38, and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
[4] The PD-1/CD3 bispecific antibody or antibody fragment thereof according to
the
preceding item [1] or [2], wherein
(i) the VH of the first arm specifically binding to PD-1 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 9,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 10,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 11;
and
(ii) the VH of the second arm specifically binding to CD3 has:
CA 03089722 2020-07-27
\
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
[5] The PD-1/CD3 bispecific antibody or antibody fragment thereof according to
the
5 preceding item [1] or [2], wherein
(i) the VH of the first arm specifically binding to PD-1 has
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 12,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 13,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 14,
and
(ii) the VH of the second arm specifically binding to CD3 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
[6] The PD-1/CD3 bispecific antibody or antibody fragment thereof according to
the
preceding item [1] or [2], wherein
(i) the VH of the first arm specifically binding to PD-1 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 15,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 16,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 17;
and
(ii) the VH of the second arm specifically binding to CD3 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
[7] The PD-1/CD3 bispecific antibody or an antibody fragment thereof according
to the
preceding item [1] or [2], wherein
(i) the VH of the first arm specifically binding to PD-1 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 18,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 19,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 20;
and
(ii) the VH of the second arm specifically binding to CD3 has:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
CA 03089722 2020-07-27
6
[8] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein the first arm specifically binding to PD-1 contains a VH having;
(a) a VH-CDR1 comprising an amino acid sequence represented by HYJ1LH [wherein
.11
represents G (glycine) or A (alanine), and alphabets represented by .11 or
other represent
one-letter amino-acid abbreviation, respectively],
(b) a VH-CDR2 comprising an amino acid sequence represented by
WJ2NTNTU2NPTX2AQGFTG [wherein J2 represents L (leucine) or I (isoleucine), U2
represents E (glutamic acid) or G (glycine), X2 represents F (phenylalanine)
or Y (tyrosine),
and alphabets represented by J2, U2 or X2, or other represent the same as the
above,
respectively], and
(c) a VH-CDR3 comprising an amino acid sequence represented by
GDJ3VVPTTIWNYYU3X3MZ3V [wherein J3 represents M (methionine) or L (leucine),
U3
represents H (histidine) or Y (tyrosine), X3 represents F (phenylalanine) or Y
(tyrosine), Z3
represents D (aspartic acid) or E (glutamic acid), and alphabets represented
by J3, U3, X3 or Z3,
or other alphabets represent the same as the above, respectively], and;
wherein the second arm specifically binding to CD3 contains the VH having:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
[9] The PD-1/CD3 bispecific antibody or antibody fragment thereof according to
the
preceding item [8], wherein
(a) J1 represents G (glycine), J2 represents L (leucine), U2 represents E
(glutamic acid), X2
represents F (phenylalanine), J3 represents M (methionine), U3 represents H
(histidine), X3
represents F (phenylalanine), and Z3 represents D (aspartic acid);
(b) .1' represents G (glycine), J2 represents I (isoleucine), U2 represents G
(glycine), X2
represents Y (tyrosine), J3 represents L (leucine), U3 represents H
(histidine), X3 represents Y
(tyrosine), and Z3 represents E (glutamic acid);
(c) .11 represents A (alanine), J2 represents L (leucine), U2 represents E
(glutamic acid), X2
represents Y (tyrosine), J3 represents M (methionine), U3 represents Y
(tyrosine), X3
represents Y (tyrosine), and Z3 represents D (aspartic acid); or
(d) J1 represents A (alanine), J2 represents L (leucine), U2 represents E
(glutamic acid), X2
represents F (phenylalanine), J3 represents M (methionine), U3 represents H
(histidine), X3
CA 03089722 2020-07-27
3
7
represents F (phenylalanine), and Z3 represents D (aspartic acid).
[10] The PD-1/CD3 bispecific antibody or an antibody fragment thereof
according to any one
of the preceding items [1] to [9], wherein the framework region 1
(hereinafter, may be
abbreviated as "FR1"), the framework region 2 (hereinafter, may be abbreviated
as "FR2")
and the framework region 3 (hereinafter, may be abbreviated as "FR3") in a
framework region
(hereinafter, "framework" may be abbreviated as "FR") in the VH of the first
arm specifically
binding to PD-1 correspond to amino acid sequences encoded by the germ-line V
gene
IGHV7-4-1 or gene thereof with somatic mutation(s), respectively.
[11] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [10], wherein the framework 4 (hereinafter, "the framework 4"
may be
abbreviated as "FR4") region in the VH of the first arm specifically binding
to PD-1 includes
an amino acid sequence (excluding the amino acid sequence included in the VH-
CDR3)
encoded by the germ-line J gene JH6c or gene thereof with somatic mutation(s).
[12] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [10] or [11], wherein the FR region in the VH of the first arm
specifically
binding to PD-1 is encoded by the germ-line V gene IGHV7-4-1 with somatic
mutation(s),
and wherein the FR region contains the FR1 region in which in the amino acid
sequence set
forth in SEQ ID No. 21, by the somatic mutation, lysine at position 13 is or
may be
substituted with glutamine, alanine at position 16 is or may be substituted
with valine, or
lysine at position 19 is or may be substituted with methionine, respectively,
or which are or
may be carried out in arbitrary combination of a plurality thereof.
[13] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [10] to [12], wherein the FR region of the VH in the first
arm specifically
binding to PD-1 is encoded by the germ-line V gene IGHV7-4-1 with somatic
mutation(s),
and wherein the FR region contains the FR2 region in which in the amino acid
sequence set
forth in SEQ ID No. 21, valine at position 37 is or may be substituted with
leucine, by the
somatic mutation.
[14] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [10] to [13], wherein the FR region of the VH in the first
arm specifically
binding to PD-1 is encoded by the germ-line V gene IGHV7-4-1 with somatic
mutation(s),
and wherein the FR region contains the FR3 region in which in the amino acid
sequence set
forth in SEQ ID No. 21, by the somatic mutation, serine at position 77 is or
may be
substituted with threonine or cysteine at position 84 is or may be substituted
with serine or
CA 03089722 2020-07-27
3
8
asparagine, respectively, or which are or may be carried out in arbitrary
combination of a
plurality thereof.
[15] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [10] to [14], wherein the FR4 region of the VH of the
first arm
specifically binding to PD-1 is encoded by the germ-line J gene JH6c with
somatic
mutation(s) (excluding the gene region encoding VH-CDR3), and wherein in the
amino acid
sequence (Trp-Gly-Lys-Gly-Thr-Thr*-Val-Thr-Val-Ser-Ser)(SEQ ID No. 41) of the
FR4
region, lysine (Lys) is or may be substituted with glutamine or asparagine
and/or threonine
(Thr) marked with an asterisk is or may be substituted with leucine.
[16] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [15], wherein the VII of the first arm specifically
binding to PD-1
comprises the amino acid sequence set forth in any one selected from SEQ ID
No. 1, SEQ ID
No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5, or an amino acid sequence
having an
identity of at least 80%, 90%, 95%, 98% or 99% to amino acid sequence thereof.
[17] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] and [3] to [7], wherein the VH of the first arm
specifically binding to
PD-1 comprises the amino acid sequence set forth in any one selected from SEQ
ID No. 1,
SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5.
[18] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [17], wherein the VH of the second arm specifically
binding to CD3
comprises an amino acid sequence set forth in SEQ ID No. 36 or an amino acid
sequence
having an identity of at least 80%, 90%, 95%, 98% or 99% to amino acid
sequence thereof.
[19] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] and [3] to [18], wherein the VH of the second arm
specifically binding
to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
[20] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [1], wherein the VII of the first arm specifically binding to
PD-1 comprises
the amino acid sequence set forth in any one selected from SEQ ID No. 1, SEQ
ID No. 2,
SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5; and the VII of the second arm
specifically
binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
[21] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein the VII
of the first arm specifically binding to PD-1 comprises the amino acid
sequence set forth in
CA 03089722 2020-07-27
9
any one selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4,
and SEQ
ID No. 5, or an amino acid sequence having an identity of at least 80%, 90%,
95%, 98% or
99% to amino acid sequence thereof; and wherein the VH of the second arm
specifically
binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36 or
an amino
acid having an identity of at least 80%, 90%, 95%, 98% or 99% to amino acid
sequence
thereof.
[22] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [1] or [3], wherein the VH of the first arm specifically
binding to PD-1
comprises the amino acid sequence set forth in SEQ ID No. 1; and wherein the
VII of the
second arm specifically binding to CD3 comprises the amino acid sequence set
forth in SEQ
ID No. 36.
[23] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [1] or [4], wherein the VH of the first arm specifically
binding to PD-1
comprises the amino acid sequence set forth in SEQ ID No. 2; and wherein the
VH of the
second arm specifically binding to CD3 comprises the amino acid sequence set
forth in SEQ
ID No. 36.
[24] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [1] or [5], wherein the VII of the first arm specifically
binding to PD-1
comprises the amino acid sequence set forth in SEQ ID No. 3; and wherein the
VH of the
second arm specifically binding to CD3 comprises the amino acid sequence set
forth in SEQ
ID No. 36.
[25] The PD-1/CD3 bispecific antibody or an antibody fragment thereof
according to the
preceding item [1] or [6], wherein the VH of the first arm specifically
binding to PD-1
comprises the amino acid sequence set forth in SEQ ID No. 4; and wherein the
VH of the
second arm specifically binding to CD3 comprises the amino acid sequence set
forth in SEQ
ID No. 36.
[26] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [1] or [7], wherein the VH of the first arm specifically
binding to PD-1
comprises the amino acid sequence set forth in SEQ ID No. 5; and wherein the
VH of the
second arm specifically binding to CD3 comprises the amino acid sequence set
forth in SEQ
ID No. 36.
[27] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [26], wherein the first arm specifically binding to
PD-1 and/or the
CA 03089722 2020-07-27
second arm specifically binding to CD3 has a light chain variable region
(hereinafter, "light
chain variable region" may be abbreviated as "VL") having
(a) a complementary determining region 1 of light chain variable region
(hereinafter, the
"complementary determining region 1 of light chain variable region" may be
abbreviated as
5 "VL-CDR1") comprising an amino acid sequence set forth in SEQ ID No. 26;
(b) a complementary determining region 2 of light chain variable region
(hereinafter, the
"complementary determining region 2 of light chain variable region" may be
abbreviated as
"VL-CDR2") comprising an amino acid sequence set forth in SEQ ID No. 27; and
(c) a complementary determining region 3 of light chain variable region
(hereinafter, the
10 "complementary determining region 3 of light chain variable region" may
be abbreviated as
"VL-CDR3") comprising an amino acid sequence set forth in SEQ ID No. 28,
respectively.
[28] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [27], wherein the first arm specifically binding to
PD-1 and/or the
second arm specifically binding to CD3 have the VL comprising an amino acid
sequence set
forth in SEQ ID No. 25, respectively.
[29] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein (A) the
first arm specifically binding to PD-1 has the VH comprising the amino acid
sequence set
forth in any one selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ
ID No. 4,
and SEQ ID No. 5, and the VL comprising the amino acid sequence set forth in
SEQ ID No.
25; and
(B) the second arm specifically binding to CD3 has the VH comprising the amino
acid
sequence set forth in SEQ ID No. 36; and the VL comprising the amino acid
sequence set
forth in SEQ ID No. 25.
[30] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein the first arm specifically binding to PD-1 cross-competes for (1) the
binding to PD-1
with the first arm specifically binding to PD-1 having a VH comprising the
amino acid
sequence set forth in any one selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID
No. 3,
SEQ ID No. 4, and SEQ ID No. 5; and the VL comprising the amino acid of SEQ ID
No. 25,
or (2) the binding to PD-1 with a variable region of a monoclonal antibody
specifically
binding to PD-1 having the same VH and VL.
[31] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
CA 03089722 2020-07-27
11
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein the
binding to PD-1 with the first arm specifically binding to PD-1 is cross-
competed (1) by the
first arm specifically binding to PD-1 having an VH comprising the amino acid
sequence set
forth in any one selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ
ID No. 4,
and SEQ ID No. 5; and the VL comprising the amino acid of SEQ ID No. 25, or
(2) by a
variable region of a monoclonal antibody specifically binding to PD-1 having
the same VH
and VL.
[32] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to item [30]
or [31], wherein the second arm specifically binding to CD3 further cross-
competes for (1)
the binding to CD3 with the second arm specifically binding to CD3 having the
VH
comprising the amino acid sequence set forth SEQ ID No. 36; and the VL
comprising the
amino acid sequence set forth in SEQ ID No. 25, or (2) the binding to CD3 with
a variable
region of a monoclonal antibody specifically binding to CD3 having the same VH
and VL.
[33] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to item [30]
or [31], wherein the second arm specifically binding to CD3 contains a VH
having:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No.37;
(b) theVH-CDR2 comprising the amino acid sequence set forth in SEQ ID No.38;
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No.39.
[34] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
items [30], [31] and [33], wherein the VH in the second arm specifically
binding to CD3
comprises the amino acid sequence set forth in SEQ ID No. 36 or the amino acid
sequence
having an identity of at least 80%, 90%, 95%, 98% or 99% to amino acid
sequence thereof.
[35] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to item [30]
or [31], wherein the VH of the second arm specifically binding to CD3
comprises the amino
.. acid sequence set forth in SEQ ID No. 36.
[36] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
items [30], [31], and [33] to [35], wherein the second arm specifically
binding to CD3 has the
VL having:
(a) the VL-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 26;
(b) the VL-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 27;
and
(c) the VL-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 28.
[37] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
items [30], [31], and [33] to [35], wherein the second arm specifically
binding to CD3 has the
CA 03089722 2020-07-27
12
VL comprising the amino acid sequence set forth in SEQ ID No. 25.
[38] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [37], wherein the PD-1/CD3 bispecific antibody is
an IgG antibody.
[39] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [38], wherein the IgG antibody in the preceding item [38] is an
IgGi or IgG4
antibody.
[40] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [38], wherein the IgG antibody in the preceding item [38] is an
IgGI antibody.
[41] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
.. preceding item [38], wherein the IgG antibody in the preceding item [38] is
an IgG4 antibody.
[42] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [40], wherein in two heavy chain constant regions of the IgGI
antibody in the
preceding item [40], leucines at position 235 according to the EU numbering
system are
substituted with glycine and/or glycines at position 236 according to the EU
numbering
system are substituted with arginine, respectively.
[43] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [40] or [42], wherein in a constant region of heavy chain
having the VH of the
first arm specifically binding to PD-1, both of leucine at position 351
according to the EU
numbering system and threonine at position 366 according to the EU numbering
system are
.. substituted with lysine, and in a constant region of heavy chain having the
VH of the second
arm specifically binding to CD3, leucine at position 351 according to the EU
numbering
system is substituted with aspartic acid and leucine at position 368 according
to the EU
numbering system is substituted with glutamic acid.
[44] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [40] or [42], wherein in a constant region of heavy chain
having the VII of the
first arm specifically binding to PD-1, leucine at position 351 according to
the EU numbering
system is substituted with aspartic acid and leucine at position 368 according
to the EU
numbering system is substituted with glutamic acid, and in a constant region
of heavy chain
having the VH of the second arm specifically binding to CD3, both of leucine
at position 351
according to the EU numbering system and threonine at position 366 according
to the EU
numbering system are substituted with lysine.
[45] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [40] and [42] to [44], wherein in two heavy chain constant
regions of the
CA 03089722 2020-07-27
13
IgGI antibody in any one of the preceding items [40] and [42] to [44], each
lysine at position
447 according to the EU numbering system is deleted.
[46] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [41], wherein in two heavy chain constant regions of the IgG4
antibody in the
preceding item [41], serines at position 228 according to the EU numbering
system are
substituted with proline, respectively.
[47] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [38], [40], [42] and [44], wherein the heavy chain
having the VH of
the first arm specifically binding to PD-1 has a heavy chain constant region
comprising an
amino acid sequence set forth in SEQ ID No. 23.
[48] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [38], [40], [42], [44] and [47], wherein the heavy
chain having the
VH of the second arm specifically binding to CD3 has a heavy chain constant
region
comprising an amino acid sequence set forth in SEQ ID No. 24.
[49] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [48], wherein the light chain having the VL of the
first arm
specifically binding to PD-1 and/or the light chain having VL of the second
arm specifically
binding to CD3 has/have a light chain constant region comprising an amino acid
sequence set
forth in SEQ ID No. 29.
[50] A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the
first arm
specifically binding to PD-1 and the second arm specifically binding to CD3,
wherein:
(A) a heavy chain having the VH of the first arm specifically binding to PD-1
has the VH
comprising the amino acid sequence set forth in any one selected from SEQ ID
No. 1, SEQ
ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5, and the heavy chain
constant
region comprising the amino acid sequence set forth in SEQ ID No. 23;
(B) a light chain having the VL of the first arm specifically binding to PD-1
has the VL
comprising the amino acid sequence set forth in SEQ ID No. 25, and the light
chain constant
region comprising the amino acid sequence set forth in SEQ ID No. 29;
(C) a heavy chain having the VH of the second arm specifically binding to CD3,
has the VH
comprising the amino acid sequence set forth in SEQ ID No. 36, and the heavy
chain constant
region comprising the amino acid sequence set forth in SEQ ID No. 24; and
(D) a light chain having the VL of the second aim specifically binding to CD3
has the VL
comprising the amino acid sequence set forth in SEQ ID No. 25, and the light
chain constant
CA 03089722 2020-07-27
,
V
1
14
region comprising the amino acid sequence set forth in SEQ ID No. 29.
[51] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [50], wherein the first arm specifically binding to
PD-1 allows an
interaction between PD-1 and PD-Li.
[52] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [51], wherein cytolcine production is sufficiently
reduced.
[53] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [50], wherein the first arm specifically binding to
PD-1 allows the
interaction between the PD-1 and PD-L1, and wherein cytolcine production is
sufficiently
reduced.
[54] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to the
preceding item [52] or [53], wherein the cytolcine includes at least IL-2, IFN-
y or INF-a.
[55] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [54], wherein PD-1 is human PD-1, and CD3 is human
CD3,
respectively.
[56] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [55], wherein CD3 is CD3c.
[57] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [56], wherein the PD-1/CD3 bispecific antibody is a
monoclonal
antibody.
[58] The PD-1/CD3 bispecific antibody or antibody fragment thereof according
to any one of
the preceding items [1] to [57], wherein the PD-1/CD3 bispecific antibody is
an isolated
antibody.
[1-1] A pharmaceutical composition including the PD-1/CD3 bispecific antibody
or antibody
fragment thereof according to any one of the preceding items [1] to [58] and a
pharmaceutically acceptable carrier.
[2-1] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating autoimmune disease, containing the PD-1/CD3 bispecific
antibody or
antibody fragment thereof according to any one of the preceding items [1] to
[58] as an active
ingredient.
[2-2] The pharmaceutical agent according to the preceding item [2-1], wherein
the
autoimmune disease includes Behcet's disease, systemic lupus erythematosus,
chronic discoid
lupus erythematosus, multiple sclerosis (systemic scleroderma, and progressive
systemic
CA 03089722 2020-07-27
1
sclerosis), scleroderma, polymyositis, dermatomyositis, periarteritis nodosa
(polyarteritis
nodosa, and microscopic polyangiitis), aortitis syndrome (Takayasu's
arteritis), malignant
rheumatoid arthritis, rheumatoid arthritis, juvenile idiopathic arthritis,
spondyloarthritis,
mixed connective tissue disease, Sjogren's syndrome, adult Still's disease,
vasculitis, allergic
5 granulomatous vasculitis, hypersensitivity vasculitis, rheumatoid
vasculitis, large vessel
vasculitis, ANCA associated vasculitis (e.g., granulomatosis with polyangiitis
and
eosinophilic granulomatosis with polyangiitis), Cogan's syndrome, RS3PE,
temporal arteritis,
pobutyalgia rheumatica, fibromyalgia, antiphospholipid antibody syndrome,
eosinophilic
fasciitis, IgG4-related disease (e.g., primary sclerosing cholangitis,
autoimmune insulitis),
10 Guillain-Barre syndrome, myasthenia gravis, chronic atrophic gastritis,
autoimmune hepatitis,
non-alcoholic steatohepatitis, primary biliary cirrhosis, Goodpasture's
syndrome, rapidly
progressive glomerulonephritis, megaloblastic anemia, autoimmune hemolytic
anemia,
pernicious anemia, autoimmune neutropenia, idiopathic thrombocytopenic
purpura, Basedow
disease (Graves' disease (hyperthyroidism)), Hashimoto disease, autoimmune
adrenal
15 insufficiency, primary hypothyroidism, Addison's disease (chronic
hypoadrenocorticism),
idiopathic Addison's disease, type I diabetes mellitus, slowly progressive
type I diabetes
mellitus (latent autoimmune diabetes in adult), focal scleroderma, psoriasis,
psoriatic arthritis,
bullous pemphigoid, pemphigus, pemphigoid, gestational herpes, linear IgA
bullous
dermatosis, acquired epidermolysis bullosa, alopecia areata, vitiligo,
vitiligo vulgaris,
neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy,
multifocal motor
neuropathy, sarcoidosis, giant cell arteritis, amyotrophic lateral sclerosis,
Harada disease,
autoimmune optic neuropathy, idiopathic azoospermia, habitual abortion,
inflammatory bowel
disease (e.g., ulcerous colitis, and Crohn's disease), celiac disease,
ankylosing spondylitis,
severe asthma, chronic urticarial, transplantation immunity, familial
mediterranean fever,
eosinophilic chronic rhinosinusitis, dilated cardiomyopathy, systemic
mastocytosis, or
inclusion body myositis.
[2-3] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating graft-versus-host disease (GVHD), containing the PD-1/CD3
bispecific
antibody or antibody fragment thereof according to any one of the preceding
items [1] to [58]
as an active ingredient.
[2-4] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating type I diabetes mellitus, containing the PD-1/CD3
bispecific antibody or
antibody fragment thereof according to any one of the preceding items [1] to
[58] as an active
CA 03089722 2020-07-27
16
ingredient, and being administered together with any one or more selected from
an insulin
formulation (e.g., human insulin, insulin glargine, insulin lispro, insulin
detemir, insulin aspart,
and the like.), sulfonylurea agent (e.g., glibenclamide, gliclazide, or
glimepiride), quick-acting
insulin secretion promoter (e.g., nateglinide), biguanide preparation (e.g.,
metformin), insulin
resistance improving agent (e.g., pioglitazone), a-glucosidase inhibitor
(e.g., acarbose,
voglibose, and the like.), diabetic neuropathy therapeutic agent (e.g.,
epalrestat, mexiletine,
imidapril, and the like.), GLP-1 analog preparation (e.g., liraglutide,
exenatide, lixisenatide,
and the like.), and DPP-4 inhibitor (e.g., sitagliptin, vildagliptin,
alogliptin, and the like.).
[2-5] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating multiple sclerosis, containing the PD-1/CD3 bispecific
antibody or
antibody fragment thereof according to any one of the preceding items [1] to
[58] as an active
ingredient, and being administered together with any one or more selected from
a steroid
agent (e.g., cortisone acetate, hydrocortisone, hydrocortisone sodium
phosphate,
hydrocortisone sodium succinate, fludrocortisone acetate, prednisolone,
prednisolone acetate,
prednisolone sodium succinate, prednisolone butylacetate, prednisolone sodium
phosphate,
halopredone acetate, methylprednisolone, methylprednisolone acetate,
methylprednisolone
sodium succinate, triamsinolone, triamsinolone acetate, triamsinolone
acetonide,
dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate,
dexamethasone
palmitate, paramethasone acetate, or betamethasone and the like.), interferon
13-1a, interferon
13-1b, glatiramer acetate, mitoxantrone, azathioprine, cyclophosphamide,
cyclosporin,
methotrexate, cladribine, adrenocorticotropic hormone (ACTH), corticotropin,
mizoribine,
tacrolimus, fingolimod, and aletntuzumab.
[2-6] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating systemic lupus erythematosus, containing the PD-1/CD3
bispecific
antibody or antibody fragment thereof according to any one of the preceding
items [1] to [58]
as an active ingredient, and being administered together with any one or more
selected from a
steroid agent (e.g., the steroid agents mentioned in the preceding item [2-
5]), an
immunosuppressive agent (e.g., cyclosporin, tacrolimus, or fingolimod), and
belimumab.
[2-7] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating rheumatoid arthritis, containing the PD-1/CD3 bispecific
antibody or
antibody fragment thereof according to any one of the preceding items [1] to
[58] as an active
ingredient, and being administered together with any one or more selected from
a steroid
agent (e.g., the steroid agents mentioned in the preceding item [2-5]), anti-
rheumatic agent
CA 03089722 2020-07-27
17
(e.g., methotrexate, sulfasalazine, bucillamine, leflunomide, mizoribine,
tacrolimus, and the
like.), anti-cytokine agent (e.g., infliximab, adalimumab, tocilizumab,
etanercept, golimumab,
sertolizumab.), and abatacept.
[2-8] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating autoimmune disease, containing the PD-1/CD3 bispecific
antibody or
antibody fragment thereof according to any one of the preceding items [1] to
[58] as an active
ingredient, and being administered together with any one or more of agents
described in the
preceding items [2-4] to [2-7].
[2-9] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating diseases mentioned in the preceding items [2-4] to [2-8],
being
administered to the patient whom any one or more of drugs mentioned in the
preceding items
[2-4] to [2-7] is/are administered.
[2-10] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating diseases mentioned in the preceding items [2-4] to [2-8],
being
administered after administration of any one or more of drugs mentioned in the
preceding
items [2-4] to [2-7].
[2-11] A pharmaceutical agent for preventing, suppressing symptom progression
or recurrence
of, and/or treating diseases mentioned in the preceding items [2-4] to [2-8],
being
administered before administration of any one or more of drugs mentioned in
the preceding
items [2-4] to [2-7].
[3-1] An intravenous injection formulation including the PD-1/CD3 bispecific
antibody or
antibody fragment thereof according to any one of the preceding items [1] to
[58] and a
pharmaceutically acceptable carrier.
[3-2] The intravenous injection formulation according to the above-mentioned
[3-1] for use in
prophylaxis, suppression of progress of symptoms, suppression of recurrence
and/or therapy
for autoimmune disease.
[3-3] The intravenous injection formulation according to the preceding item [3-
1] or [3-2] for
use in drip infusion.
[4-1] An isolated polynucleotide or fragment thereof encoding a heavy chain
having a VH of
the first arm specifically binding to PD-1 constituting any one of PD-1/CD3
bispecific
antibody selected from the preceding items [1] to [58].
[4-2] An isolated polynucleotide or fragment thereof encoding a VH of the
first arm
specifically binding to PD-1 constituting any one of PD-1/CD3 bispecific
antibody selected
CA 03089722 2020-07-27
1
1
18
from the preceding items [1] to [58].
[4-3] The isolated polynucleotide or fragment thereof according to the
preceding items [4-1]
or [4-2], wherein the VH of the first arm specifically binding to PD-1 is
encoded by a
polynucleotide comprising a sequence set forth in any one selected from SEQ ID
Nos. 30 to
34.
[4-4] An isolated polynucleotide or a fragment thereof having a polynucleotide
comprising a
sequence set forth in any one selected from SEQ ID Nos. 30 to 34.
[5-1] An expression vector having a polynucleotide according to any of the
preceding items
[4-1] to [4-4].
[6-1] An animal cell, into which the expression vector of the preceding item
[5-1] is
transfected, or which is transformed by the transfected vector.
[7-1] A method for preventing, suppressing symptom progression or recurrence
of, and/or
treating autoimmune disease, comprising administering an effective amount of
the PD-1/CD3
bispecific antibody or antibody fragment thereof according to any one of the
preceding items
[1] to [58] to a patient.
[8-1] A PD-1/CD3 bispecific antibody or antibody fragment thereof selected
from the
preceding items [1] to [58] in use for preventing, suppressing symptom
progression or
recurrence of, and/or treating autoimmune disease.
[9-1] Use of the PD-1/CD3 bispecific antibody or antibody fragment thereof
selected from the
preceding items [1] to [58] for manufacturing a pharmaceutical for preventing,
suppressing
symptom progression or recurrence of, and/or treating autoimmune disease.
[10-1] An isolated anti-PD-1 monoclonal antibody or antibody fragment thereof,
which
cross-competes for binding to PD-1 with an antibody specifically binding to PD-
1 having the
VH comprising the amino acid sequence set forth in any one selected from SEQ
ID No. 1,
SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5, and the VL
comprising the
amino acid sequence of SEQ ID No. 25.
[10-2] An isolated anti-PD-1 monoclonal antibody or an antibody fragment
thereof, wherein
the binding to PD-1 with the isolated anti-PD-1 monoclonal antibody or
antibody fragment
thereof is cross-competed by an antibody specifically binding to PD-1 having
the VH
comprising the amino acid sequence set forth in any one selected from SEQ ID
No. 1, SEQ
ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5, and the VL comprising
the amino
acid sequence of SEQ ID No. 25.
[10-3] An isolated anti-PD-1 monoclonal antibody or antibody fragment thereof,
having any
CA 03089722 2020-07-27
19
one of VH selected from:
(A) the VH having:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 6,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 7,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 8,
(B) the VH having:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 9,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 10,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 11,
(C) the VH having:
(a) theVH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 12,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 13,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 14,
(D) the VH having:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 15,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 16,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 17,
and
(E) the VH having:
(a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 18,
(b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 19,
and
(c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 20,
and the
VL having:
(a) the VL-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 26,
(b) the VL-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 27,
and
(c) the VL-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 28.
[10-4] The isolated anti-PD-1 monoclonal antibody or antibody fragment thereof
according to
the preceding item [10-3], wherein one to five arbitrary amino acid residue(s)
in any one or
more of the CDR(s) selected from the VH-CDR1, VH-CDR2 and VH-CDR3 may be
substituted with other amino acid(s) (preferably, conservative amino acid(s)
thereof).
.. [10-5] The isolated anti-PD-1 monoclonal antibody or antibody fragment
thereof according to
the preceding item [10-3] or [10-4], having the VH comprising the amino acid
sequence set
forth in any one selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ
ID No. 4,
and SEQ ID No. 5, or the VH comprising the amino acid sequence having at least
80%, 90%,
CA 03089722 2020-07-27
1
95%, 98% or 99% identity of amino acid sequence thereof, and the VL comprising
the amino
acid sequence set forth in SEQ ID No. 25.
[10-6] The isolated anti-PD-1 monoclonal antibody or antibody fragment thereof
according to
any one of the preceding items [10-1] to [10-5], wherein the PD-1 is human PD-
1.
5 [10-7] The isolated anti-PD-1 monoclonal antibody or antibody fragment
thereof according to
any one of the preceding items [10-1] to [10-6], wherein the anti-PD-1
antibody is an IgG
antibody.
[10-8] The isolated anti-PD-1 monoclonal antibody or antibody fragment thereof
according to
the preceding item [10-7], wherein the IgG antibody described in the preceding
item [10-7] is
10 an IgGi antibody or IgG4 antibody.
[10-9] The isolated anti-PD-1 monoclonal antibody or antibody fragment thereof
according to
the preceding item [10-7], wherein the IgG antibody described in the preceding
item [10-7] is
an IgGI antibody.
[10-10] The isolated anti-PD-1 monoclonal antibody or antibody fragment
thereof according
15 to the preceding item [10-7], wherein the IgG antibody described in the
preceding item [10-7]
is an IgG4 antibody.
Effects of Invention
[0012]
20 Since the inducibility of cytokine production of the PD-1/CD3
bispecific antibody of
the present invention is reduced, the occurrence of infusion reaction or
cytokine release
syndrome after administration is suppressed. Furthermore, the PD-1/CD3
bispecific
antibody allows interaction between the PD-1 and PD-L1, and is expected to
enhance or
sustain the effect on prevention, suppression of symptom progression or
recurrence of, and/or
therapy for autoimmune disease.
Brief Description of the Drawings
[0013]
Fig. 1 shows each amino acid sequence of VL and constant region of common
light
chain.
Fig. 2 shows each CDR amino acid sequence in the VL of common light chain.
Fig. 3 shows the amino acid sequences encoded by germ-line V genes: IGHV7-4-1
and IGHV3-33, respectively.
CA 03089722 2020-07-27
21
Fig. 4 shows a sequence alignment among the VH of each clone of antibodies
specifically binding to PD-I (hereinafter, which may be abbreviated as "anti-
PD-1 antibody")
and germ-line genes IGHV7-4-1 and JH6c. In the drawing, in the amino acid
sequence of
each clone, "-" represents the same amino acid as that of the corresponding
germ-line gene
IGHV7-4-1 or JH6c, and a part with simplified characters of each amino acid
represents an
amino acid different from that of the germ-line gene.
Fig. 5 shows the VH amino acid sequence of each anti-PD-1 antibody clone.
Fig. 6 shows each CDR amino acid sequence in VH of each anti-PD-1 antibody
clone.
Fig. 7 shows the VH amino acid sequence of the CD3-2 clone as an antibody
specifically binding to CD3 (hereinafter, which may be abbreviated as "anti-
CD3 antibody").
Fig. 8 shows the amino acid sequence of each CDR in the VH of the CD3-2 clone
as
an anti-CD3 antibody.
Fig. 9 shows the amino acid sequence of constant region in each heavy chain of
the
PD-1/CD3 bispecific monoclonal antibody.
Fig. 10 shows the VH amino acid sequence of the anti-CD3 antibody clone 15C3
described in W02005/118635. Note here that the underlined amino acid
represents the 55th
glycine which is converted into alanine in producing the clone CD3-1.
Fig. 11 shows Biacore measurement results demonstrating the binding activity
to
PD-1 and CD3 of each PD-1/CD3 bispecific monoclonal antibody clone.
Fig. 12 shows flow cytometry demonstrating the simultaneous binding property
to
PD-1 and CD3 of each PD-1/CD3 bispecific monoclonal antibody clone.
Fig. 13 shows flow cytometry demonstrating influence on the PD-1/PD-L1
interaction of each PD-1/CD3 bispecific monoclonal antibody clone.
Fig. 14 shows effects on IFN-y production from activated human T cells of each
PD-1/CD3 bispecific monoclonal antibody clone. Note here that in the drawing,
"Ctrl"
represents control group.
Fig. 15 shows therapeutic effects of the PD-1/CD3 bispecific monoclonal
antibody
clones (PD1-1(Bi) and PD1-2(Bi)) in an experimental allergic encephalomyelitis
mouse
model (EAE model).
Fig. 16 shows therapeutic effects of the PD-1/CD3 bispecific monoclonal
antibody
clones (PD1-3(Bi) and PD1-4(Bi)) in an experimental allergic encephalomyelitis
mouse
model.
CA 03089722 2020-07-27
1
22
Fig. 17 shows therapeutic effects of the PD-1/CD3 bispecific monoclonal
antibody
clones (PD1-5(Bi) and PD1-6(Bi)) in an experimental allergic encephalomyelitis
mouse
model.
Fig. 18 shows the results of effect on cytokine production from human
peripheral
blood mononuclear cell of each PD-1/CD3 bispecific monoclonal antibody clone.
Fig. 19 shows the cross-competitive activity of PD1-5(Bi) against the binding
to
PD-1 of each PD-1/CD3 bispecific monoclonal antibody clone.
Description of Embodiments
[0014]
PD-1 (Programmed Cell Death-1) in human is a membrane-type protein composed of
the amino acid sequence represented by GenBank accession number NP_005009. In
the
present specification, the term "PD-1", unless specifically defined otherwise,
may be used as
a meaning including all the isoforms thereof, and variants thereof in which
epitopes for the
"first arm specifically binding to PD-1" in the present inventions are
conserved. In the
present invention, PD-1 is preferably human PD-1.
[0015]
CD3 is the membrane-type protein which forms T-cell receptor complex by
association with a T-cell receptor. In the present specification, the term
"CD3", unless
specifically defined otherwise, may be used as a meaning including the subtype
(c, 6, y and C
subtype), and variants thereof in which epitopes for the "second arm
specifically binding to
CD3" of the present inventions are conserved. In the present invention, CD3 is
preferably
CD3e, and human CD3, and more preferably human CD3e.
[0016]
In the present specification, the term "isolate" means that a single
substantially pure
component is obtained by being identified, separated and/or purified from
impurities
containing a plurality of or myriad number of components extracted from a host
cell.
[0017]
In the present specification, the term "monoclonal antibody" means an antibody
obtained from a substantially homogeneous antibody group binding to the same
specific
antigen.
[0018]
In this specification, the term "bispecific antibody" means an antibody having
CA 03089722 2020-07-27
23
binding specificity to two different antigen molecules or epitopes in a
molecule.
Furthermore, the term "bispecific monoclonal antibody" means a bispecific
antibody obtained
from a substantially homogeneous antibody group.
[0019]
The present invention relates to a bispecific antibody capable of specifically
binding
to PD-1 and CD3 (in the present specification, may be abbreviated as "PD-1/CD3
bispecific
antibody"). In the present invention, the PD-1/CD3 bispecific antibody is
preferably a
PD-1/CD3 bispecific monoclonal antibody, and more preferably an isolated PD-
1/CD3
bispecific monoclonal antibody, and further preferably an isolated human PD-
1/human CD3
bispecific monoclonal antibody. Herein, the "isolated human PD-1/human CD3
bispecific
monoclonal antibody" means an isolated bispecific monoclonal antibody for
human PD-1 and
human CD3.
[0020]
Exemplified embodiments of the PD-1 bispecific antibody include, e.g.,
diabodies,
bispecific sc(Fv)2, bispecific minibodies, bispecific F(ab1)2, bispecific
hybrid antibodies,
covalent diabodies (bispecific DART), bispecific (FvCys)2, bispecific F(abt-
zipper)2,
bispecific (Fv-zipper)2, bispecific three-chain antibodies, and bispecific
mAb2, and the like.
[0021]
The diabody is a dimer of single-chain peptides in which a VH and VL
recognizing
different antigens are linked to each other with a peptide linker (Proc. Natl.
Acad. Sci. USA,
1993, Vol. 90, No. 14, pp. 6444-6448).
[0022]
The bispecific sc(Fv)2 is a low-molecular antibody modified such that two
pairs of
VHNL in two antibodies recognizing different antigens are linked to each other
with a
peptide linker into a continuous single chain form (see J. Biological
Chemistry, 1994, 269: pp.
199-206).
[0023]
The bispecific F(abl)2 is a low-molecular antibody in which Fab' fragments of
antibodies recognizing two different antigens are covalently bonded through,
e.g., a disulfide
bond.
[0024]
The bispecific minibody is a low-molecular antibody in which low-molecular
antibody fragments modified in such a manner that the constant region CH3
domains of the
CA 03089722 2020-07-27
24
antibodies are linked to scFv recognizing different antigens is covalently
bonded by, e.g., the
disulfide bonds on the CH3 domains (see Biochemistry, 1992, Vo. 31, No .6, pp.
1579-1584).
[0025]
The bispecific hybrid antibody is an intact antibody in which heavy
chain/light chain
complexes recognizing two different antigens are covalently bound each other
by, e.g., a
disulfide bond.
[0026]
In the present invention, examples of the form of the preferable bispecific
antibody
include a bispecific hybrid antibody.
[0027]
The bispecific hybrid antibody can be produced, e.g., from a hybridoma using a
hybrid hybridoma method (see US4474893). Alternatively, the bispecific hybrid
antibody
can be produced by secretion from a mammal animal cell co-expressing four
kinds of cDNAs
respectively encoding heavy chain and light chain of antibodies recognizing
different
antigens.
[0028]
The monoclonal antibodies used in the present invention can be produced by a
hybridoma method (see, e.g., Kohler and Milstein et al., Natur (1975), Vol.
256, p.495-97,
Hongo et al., Hybridoma (1995), Vol. 14, No. 3, pp.253-260, Harlow et al.,
Antibodies: A
Laboratory Manual, (Cold Spring Harbor Laboratory Press (1988), Vol. 2) and
Hatnmerling et
al., Monoclonal Antibodies and T-Cell Hybridomas, pp.563-681 (Elsevier, N.Y.,
1981)), a
recombinant DNA method (see, e.g., US4816567), a phage display method (see,
e.g., Ladner
et al., US5223409, US5403484 and US5571698, Dower et al., US5427908 and
US5580717,
McCafferty et al., US5969108 and US6172197, and Griffiths et al., US5885793,
US6521404,
US6544731,US6555313, US6582915 and US6593081).
[0029]
An antibody or a monoclonal antibody, when being administered to human, can be
produced in a form of a chimeric antibody, a humanized antibody, or a complete
human
antibody in order to reduce or eliminate its antigenicity.
[0030]
The term "chimeric antibody" means the antibody of which the constant region
sequence and variable region sequence are derived from different mammalian.
Examples of
the chimeric antibody include an antibody of which the variable region
sequence is derived
CA 03089722 2020-07-27
from a mouse antibody and the constant region sequence is derived from a human
antibody.
The chimeric antibody can be produced by linking a gene encoding an antibody
variable
region isolated from the above-mentioned antibody-producing hybridoma isolated
by a
hybridoma method, a recombinant DNA method or a phage display method by well-
known
5 techniques, to a gene encoding the constant region of a human-derived
antibody using a
well-known method (see, e.g., Cabilly et al., US4816567).
[0031]
The term "humanized antibody" means an antibody prepared by, e.g., grafting a
complementarity determining region (CDR) sequence of an antibody derived from
a germ line
10 of a mammal other than human, such as mouse, into human framework
sequences of a human
antibody. Also, the humanized antibody can be produced by linking genes
encoding CDR
regions of an antibody isolated from the above-mentioned antibody-producing
hybridoma
isolated by the above-mentioned method, to a gene encoding a framework region
of the
human-derived antibody using a well-known method (see, e.g., Winter, US5225539
and
15 US5530101; Queen et al., US5585089 and US6180370.
[0032]
The term "human antibody" or "complete human antibody" means an antibody in
which both of a variable region composed of framework regions and CDR regions
and a
constant region are derived from human gennline imtnunoglobulin sequences. The
human
20 antibody to be used in the present invention can be produced by a method
using a mouse
transformed to produce human antibodies, e.g., Humab mouse (see, e.g., Lonberg
and Kay et
al. US5545806, US5569825, US5625126, US5633425, US5789650, US5877397,
US5661016,
US5814318, US5874299 and US5770429), a KM mouse (see, e.g., Ishida et al.,
W02002/43478), a Xeno mouse (see, e.g., US5939598, US6075181, US6114598,
25 US6150584 and US6162963), or a Tc mouse (see, e.g., Tomizuka et al.,
Proc. Natl. Acad. Sci.
USA (2000), pp.722-727). The human antibody can also be prepared using SCID
mice into
which human immune cells have been reconstructed such that human antibody
response is
made upon immunization (see, e.g., US5476996 and US5698767 to Wilson et al.).
Furthermore, the human antibody used in the present invention can also be
produced by the
above-mentioned phage display method.
[0033]
In the present specification, the term "antibody fragment" of the PD-1/CD3
bispecific antibody is a part of the full-length antibody and is an antibody
having an antigen
CA 03089722 2020-07-27
26
binding part to PD-1 and an antigen binding part to CD3. Examples thereof
include F(a131)2,
and the like. Herein, the antigen binding part means a minimum unit of an
antibody that can
bind to an antigen thereof, and e.g., it is composed of three CDRs in each of
VH and VL and
framework regions for arranging CDRs such that the target antigen can be
recognized by
combination of those CDRs.
[0034]
In the present specification, the term "common light chain" means a light
chain that
can be associated with two or more different heavy chains, and can exhibit the
binding ability
to each antigen (De Wildt RM, J. Mol. Biol. (1999), Vol. 285, pp.895901, De
Kruif et al., J.
Mol. Biol. (2009), Vol. 387, pp.548-58, W02004/009618, W02009/157771 and
W02014/051433). Preferable examples of such a common light chain include a
light chain
encoded by human lc light chain IgVx1-39*01/IGR1*01 (nomenclatures of IMGT
database)
germ-line gene (hereinafter, abbreviated as "IGVK1-39/JK1 common light
chain"). More
preferable examples include the light chain containing the VL having the CDR1
comprising
the amino acid sequence set forth in SEQ ID No. 26, the CDR2 comprising the
amino acid
sequence set forth in SEQ ID No. 27, and the CDR3 comprising the amino acid
sequence set
forth in SEQ ID No. 28, and further preferable examples include the light
chain containing the
VL comprising the amino acid sequence set forth in SEQ ID No. 25. Furthermore,
preferable examples of the constant region of the common light chain include
the light chain
constant region comprising the amino acid sequence set forth in SEQ ID No. 29.
Each
amino acid sequence of VL and the constant region of common light chain used
in the present
invention are shown in Fig. 1, and each CDR amino acid sequence of the
variable region is
shown in Fig. 2.
[0035]
In the present specification, the term "isotype" means the antibody class
(e.g., IgM or
IgG) that is encoded by heavy chain constant region genes. Preferable examples
of the
isotype for the PD-1/CD3 bispecific antibody of the present invention include
IgG, and more
preferably, IgGi or IgGa. The IgGi used herein is preferably of which the
binding to an Fc
receptor is eliminated or decreased. Specifically, the IgGi antibody of which
the binding to
the Fc receptor is eliminated or decreased can be obtained by substituting,
deleting, or
inserting arbitrary amino acid of the heavy chain constant region thereof.
Examples thereof
include an antibody in which leucine at position 235 according to the EU
numbering system is
substituted with glycine, and/or glycine at position 236 according to the EU
numbering
CA 03089722 2020-07-27
1
27
system is substituted with arginine on each of two heavy chain constant
regions or a hinge
region thereof. Furthermore, in order to reduce the heterogeneity of the
antibody, the
antibody in which an amino acid at C-terminal, e.g., lysine at position 447
according to the
EU numbering system has been deleted is preferable. Furthermore, when the
bispecific
antibody is IgG4, in order to suppress the swapping in an antibody molecule,
the variant in
which an arbitrary amino acid in the heavy chain constant region thereof is
substituted,
deleted or inserted is preferable. For example, an antibody of which serine
located in the
hinge region and at position 228 according to the EU numbering system is
substituted with
proline is preferable. Note here that in the specification, amino acid
positions assigned to
CDRs and frameworks in a variable region of an antibody are specified
according to Kabat's
numbering (see Sequences of Proteins of Immunological Interest (National
Institute of Health,
Bethesda, Md., 1987 and 1991)). Furthermore, amino acids in the constant
region are
represented according to the EU numbering system based on Kabat's amino acid
positions
(see Sequences of proteins of immunological interest, NIH Publication No. 91-
3242).
[0036]
In Fc regions of the PD-1/CD3 bispecific antibody of the present invention,
arbitrary
amino acids therein may be substituted such that two different heavy chains
are easily
associated with each other. Examples of the preferable embodiments include a
PD-1/CD3
bispecific antibody of which in the constant region of the heavy chain having
the VH of the
first arm specifically binding to PD-1, leucine at position 351 according to
the EU numbering
system is substituted with lysine, and threonine at position 366 according to
the EU
numbering system is substituted with lysine; and of which in the constant
region of the heavy
chain having the VH of the second arm specifically binding to CD3, leucine at
position 351
according to the EU numbering system is substituted with aspartic acid, and
leucine at
position 368 according to the EU numbering system is substituted with
glutatnic acid. The
examples also include a PD-1/CD3 bispecific antibody of which in the constant
region in the
heavy chain having the VH of the first arm specifically binding to PD-1,
leucine at position
351 according to the EU numbering system is substituted with aspartic acid,
and leucine at
position 368 is substituted with glutamic acid; and of which in the constant
region in the
heavy chain having the VH of the second arm specifically binding to CD3,
leucine at position
351 according to the EU numbering system is substituted with lysine, and
threonine at
position 366 according to the EU numbering system is substituted with lysine.
100371
CA 03089722 2020-07-27
28
The first arm specifically binding to PD-1
In the present specification, the "first arm specifically binding to PD-1"
(hereinafter,
which may be abbreviated as "first arm") means a part of an antibody
containing at least a VH
of an antibody specifically binding to PD-1 (hereinafter, which may be
abbreviated as
"anti-PD-1 antibody"), regardless of whether it is contained in a part of the
antibody or
antibody fragment thereof, or exists not as a part but as a single body. For
example, such a
first arm is composed of a VH of an anti-PD-1 antibody, and a VL of the common
light chain
constituting the same anti-PD-1 antibody. Furthermore, examples of the first
arm also
include a Fab part of the antibody including the VH and VL. Herein, the term
"specifically
binding to PD-1" is used as a feature that it can directly bind to PD-1 with
binding activity of
at least 1 x 10-5 M, preferably 1 x 10-7 M, and more preferably more than 1 x
10-9 M affinity
(dissociation constant (Kd value)), and does not substantially bind to other
receptor members
belonging to a so-called CD28 family receptor, e.g., at least, CD28, CTLA-4
and ICOS.
Furthermore, an "antibody" in the "antibody specifically binding to PD-1" or
in the
"anti-PD-1 antibody" means a full-length antibody composed of two heavy chains
and two
light chains linked with disulfide bonds, and preferably a monoclonal antibody
thereof.
[0038]
Herein, examples of the "first arm specifically binding to PD-1" include:
(a) the VH-CDR1 comprising the amino acid sequence represented by HYJ1LH
[wherein Ji
represents G (glycine) or A (alanine), and herein, alphabets represented by 31
or other
represent a one letter amino-acid abbreviation, respectively];
(b) the VH-CDR2 comprising the amino acid sequence represented by
WJ2NTNTU2NPTX2AQGFTG [wherein J2 represents L (leucine) or I (isoleucine), U2
represents E (g,lutamic acid) or G (glycine), X2 represents F (phenylalanine)
or Y (tyrosine),
and herein, alphabets represented by 32, U2 or X2, or other represent the same
as the above,
respectively]; and
(c) the VH-CDR3 comprising an amino acid sequence represented by
GDJ3VVPTTIWNYYU3X3MZ3V [wherein J3 represents M (methionine) or L (leucine),
U3
represents H (histidine) or Y (tyrosine), X3 represents F (phenylalanine) or Y
(tyrosine), Z3
represents D (aspartic acid) or E (glutamic acid), and herein, alphabets
represented by 33, U3,
X3 or Z3, or other alphabets represent the same as the above, respectively].
[0039]
Herein, preferable embodiments of the "first arm specifically binding to PD-1"
CA 03089722 2020-07-27
1
29
include those containing:
(la) a VH having each VH-CDR in which JI in the HYJILH sequence as VH-CDR1
represents G (glycine); in the WJ2NTNTU2NPTX2AQGFTG as VH-CDR2, J2 represents
L
(leucine), U2 represents E (glutamic acid), and X2 represents F
(phenylalanine), respectively;
in the GDJ3VVPTTIWNYYU3X3MZ3V sequence as VH-CDR3, J3 represents M
(methionine),
U3 represents H (histidine), X3 represents F (phenylalanine), and Z3
represents D (aspartic
acid), respectively;
(2a) a VH having each VH-CDR in which JI in the HYJILH sequence as VH-CDR1
represents G (glycine); in the WJ2NTNTU2NPTX2AQGFTG as VH-CDR2, J2 represents
I
(isoleucine), U2 represents G (glycine), and X2 represents Y (tyrosine),
respectively; in the
GDJ3VVPTTIWNYYU3X3MZ3V sequence as VH-CDR3, J3 represents L (leucine), U3
represents H (histidine), X3 represents Y (tyrosine), and Z3 represents E
(glutamic acid),
respectively;
(3a) a VH having each VH-CDR in which J1 in the HYJILH sequence as VH-CDR1
represents A (alanine); in the WJ2NTNTU2NPTX2AQGFTG as VH-CDR2, J2 represents
L
(leucine), U2 represents E (glutamic acid), and X2 represents Y (tyrosine),
respectively; in the
GDJ3VVPTTIWNYYU3X3MZ3V sequence as VH-CDR3, P represents M (methionine), U3
represents Y (tyrosine), X3 represents Y (tyrosine), and Z3 represents D
(aspartic acid),
respectively; and
(4a) a VH having each VH-CDR in which J1 in the HYJILH sequence as VH-CDR1
represents A (alanine); in the WJ2NTNTU2NPTX2AQGFTG as VH-CDR2, P represents L
(leucine), U2 represents E (glutamic acid), and X2 represents F
(phenylalanine), respectively;
J3 represents M (methionine), U3 represents H (histidine), in the
GDJ3VVPTTIWNYYU3X3MZ3V sequence as VH-CDR3, X3 represents F (phenylalanine),
and Z3 represents D (aspartic acid), respectively.
[0040]
Furthermore, as preferable examples of another embodiment, the "first arm
specifically binding to PD-1" include any one of the VH selected from:
(lb) the VH having VH-CDR1 comprising the amino acid sequence set forth in SEQ
ID No. 6,
the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 7, and
the
VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 8;
(2b) the VH having VH-CDR1 comprising the amino acid sequence set forth in SEQ
ID No. 9,
the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 10, and
the
CA 03089722 2020-07-27
VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 11;
(3b) the VH having the VH-CDR1 comprising the amino acid sequence set forth in
SEQ ID
No. 12, the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No.
13, and
the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 14;
5 (4b) the VH having the VH-CDR1 comprising the amino acid sequence set
forth in SEQ ID
No. 15, the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No.
16, and
the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 17; and
(5b) the VH having the VH-CDR1 comprising the amino acid sequence set forth in
SEQ ID
No. 18, the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No.
19, and
10 .. the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No.
20.
[0041]
Furthermore, the "first arm specifically binding to PD-1" of the present
invention
includes those of which 1 to 5 arbitrary amino acid residue(s) is/are
substituted with other
amino acid(s) (preferably, conservative amino acid(s) thereof) in each VH-CDR
of any one of
15 the VH selected from the above-mentioned (la) to (4a) or (lb) to (5b), and
which have
substantially the same binding activity to PD-1 as that of the original first
arm without any
substitutions with the amino acid(s). For example, as to the VH-CDR1, one
amino acid
residue is substituted with a conservative amino acid thereof. As to the VH-
CDR2 or the
VH-CDR3, one or two amino acid residues is/are substituted with the
conservative amino
20 .. acid(s) thereof, respectively. Herein, the substitution with a
conservative amino acid means
the exchangeability with a residue having a similar side-chain. For example, a
group of
amino acids having an aliphatic side-chain includes glycine, alanine, valine,
leucine, and
isoleucine; a group of amino acids having an aliphatic hydroxyl side-chain
includes serine and
threonine; a group of amino acids having amide-containing side-chain includes
asparagine
25 and glutamine; a group of amino acids having an aromatic side-chain
includes phenylalanine,
tyrosine and tryptophane; a group of amino acids having a basic side-chain
includes lysine,
arginine and histidine; and a group of amino acids having a sulfur-containing
side-chain
includes cysteine and methionine. Preferable examples of the substitution with
a
conservative amino acid include a substitution among valine, leucine and
isoleucine, a
30 substitution between phenylalanine and tyrosine, a substitution between
lysine and arginine,
and a substitution between alanine and valine, as well as a substitution
between asparagine
and glutamine. Furthermore, herein, the sentence "which have substantially the
same
binding activity to PD-1 as that of the original first arm without any
substitutions with the
CA 03089722 2020-07-27
31
amino acid(s)" mentioned above means that the binding activity to PD-1 of the
first arm
substituted with the same amino acid(s) is 95% or more, preferably 98% or
more, and more
preferably 99% or more to that of the original first arm without any
substitutions with the
same amino acid(s).
[0042]
Furthermore, the "first arm specifically binding to PD-1" in the present
invention
includes those containing a VH having each VH-CDR having the above-mentioned
specific
amino acid sequence and in which the framework of the VH is encoded by a
specific
germ-line gene or gene thereof with somatic mutation(s). For example, the VH
presented by
any one selected from the above-mentioned (la) to (4a) or (lb) to (5b) can be
encoded by the
VDJ recombinant gene in which the germ-line V gene is IGHV7-4-1 and the germ-
line J gene
is JH6c or gene thereof with somatic mutation(s). Herein, the amino acid
sequence encoded
by the germ-line V gene IGHV7-4-1 corresponds to the amino acid sequence set
forth in SEQ
ID No. 21 (Fig. 3).
[0043]
The frameworks of the VH of the first arm specifically binding to PD-1 of the
present
invention may be encoded by the germ-line VDJ recombinant gene with somatic
mutation(s).
For example, since the FR1, FR2, and FR3 of the VH presented by any one
selected from the
above-mentioned (1 a) to (4a) or (lb) to (5b) of which the germ-line V gene is
IGHV7-4-1 is
different from an amino acid sequence encoded by the IGHV7-4-1 gene at the
position of the
amino acid shown in Fig. 4, they undergo somatic mutation at each of the
positions. For
example, as to the FR1 region, in the amino acid sequence set forth in SEQ ID
No. 21, lysine
at position 13 may be substituted with glutamine, alanine at position 16 may
be substituted
with valine, or lysine at position 19 may be substituted with methionine,
respectively, or
which may be substituted in arbitrary combination of a plurality thereof. As
to the FR2
region, valine at position 37 in the amino acid sequence set forth in SEQ ID
No. 21 is
substituted with leucine. As to the FR3 region, in the amino acid sequence set
forth in SEQ
ID No. 21, seiine at position 77 may be substituted with threonine, or
cysteine at position 84
may be substituted with serine or asparagine, respectively, or which may be
substituted in
arbitrary combination of a plurality thereof. Furthermore, as to the FR4
region of VH
presented by any one selected from the above-mentioned (la) to (4a) or (lb) to
(5b), in the
amino acid sequence (Trp-Gly-Lys-Gly-Thr-Thr*-Val-Thr-Val-Ser-Ser) (SEQ ID No.
41) of
the FR4 region derived from a J gene JH6c, lysine (Lys) may be substituted
with glutamine or
CA 03089722 2020-07-27
32
asparagine, and/or threonine (Thr) marked with an asterisk may be substituted
with leucine.
Each of the FRI, FR2, FR3 and FR4 including combination of any of amino acid
substitution(s) mentioned above have no substantial effect on the functions of
the first arm
specifically binding to PD-1, and can be used as frameworks.
[0044]
Furthermore, the "first arm specifically binding to PD-1" of the present
invention
includes those having each CDR having the above-defined amino acid sequence
and in which
the FR amino acid sequences in the VH are encoded by a specific germ-line gene
or gene
thereof with somatic mutation(s). Examples of such a first arm include those
having the VH
comprising the amino acid sequence set forth in any one selected from SEQ ID
Nos. 1 to 5.
[0045]
Furthermore, examples of such a "first arm specifically binding to PD-1"
include
those having a VH comprising an amino acid sequence having at least 80%
identity,
preferably at least 90% identity, more preferably at least 95% identity,
furthermore preferably
at least 98% identity, and further more preferably at least 99% identity to
the amino acid
sequence set forth in any one selected from SEQ ID Nos. 1 to 5, and in which
the difference
from the amino acid sequence of the VH in the original first arm has no
substantial effect on
the binding activity to PD-1 (hereinafter, may be abbreviated as a "homologous
first arm").
Herein, the term "% identity" used in comparison of the identity of amino acid
sequences is
defined as the percentage of the amino acid sequence identical to the
reference amino acid
sequence (herein, the reference amino acid sequence in which the gap has been
introduced
when being needed to maximize the sequence identity.) when two sequences are
aligned.
Furthermore, herein, the sentence "the different from the amino acid sequence
of the VH in
the original first arm has no substantial effect on the binding activity to PD-
1" means that the
binding activity to PD-1 of the homologous first arm is 95% or more,
preferably 98% or more,
and more preferably 99% or more to the binding activity of the original first
arm.
[0046]
In a yet another embodiment, the "first arm specifically binding to PD-1" of
the
present invention also includes those having a variable region (herein, the
variable region
contains a VH and VL constituting it.) of the anti-PD-1 antibody cross-
competing for (1) the
binding to PD-1 with the first arm having the VH presented by any one selected
from the
above-mentioned (la) to (4a) or (lb) to (5b) or the VH comprising the amino
acid sequence
set forth in any one selected from SEQ ID Nos. 1 to 5 and the VL of the common
light chain,
CA 03089722 2020-07-27
33
or (2) the binding to PD-1 with the variable region of the monoclonal antibody
specifically
binding to PD-1 having the same VI-1 and VL, and further includes those having
the variable
region of the anti-PD-1 antibody with which the binding to PD-1 is cross-
competed (3) by the
first arm having the VII presented by any one selected from the above-
mentioned (1 a) to (4a)
or (lb) to (5b) or the VH comprising the amino acid sequence set forth in any
one selected
from SEQ ID Nos. 1 to 5 and the VL of the common light chain or (4) by the
variable region
of the monoclonal antibody specifically binding to PD-1 having the same VH and
VL.
Herein, the sentence "cross-competing for the binding to PD-1" means that it
inhibits the
binding of the first arm to PD-1, regardless of the degree thereof, by binding
to the epitope
which is the same as or partially overlaps with that of the first arm
exemplified in this
specification, or that the binding to PD-1 of the antibody binding to the
epitope which is the
same as or partially overlaps with that of the exemplified first arm is
inhibited by the
exemplified first arm, regardless of the degree thereof. The cross-competition
can be
evaluated by a competitive binding assay. For example, it can be determined
using Biacore
analysis, ELISA assay, flow cytometry, enzyme linked itnmunosorbent assay
(ELISA),
fluorescence energy transfer method (FRET) and fluorometric microvolume assay
technology
(FMAT (registered trademark)).
[0047]
Examples of the first arm cross-competing for the binding to PD-1 with the
first arm
having the VH presented by the above-mentioned (5b) and the VL of the common
light chain
include the first arm having the VII presented by any one selected from the
above-mentioned
(lb) to (4b) and the VL of the common light chain (preferably, the VL having
the VL-CDR1
comprising the amino acid sequence set forth in SEQ ID No. 26, the VL-CDR2
comprising
the amino acid sequence set forth in SEQ ID No. 27 and the VL-CDR3 comprising
the amino
acid sequence set forth in SEQ ID No. 28), and further the first arm having
the VH
comprising the amino acid sequence set forth in any one selected from SEQ ID
Nos. 1 to 4
and the VL of the common light chain (preferably, the VL comprising the amino
acid
sequence set forth in SEQ ID No. 25).
[0048]
Furthermore, examples of the first arm cross-competing for the binding to PD-1
with
the first arm having the VH presented by any one selected from the above-
mentioned (lb) to
(4b) or the VII comprising the amino acid sequence set forth in any one
selected from SEQ ID
Nos. 1 to 4 and the VL of the common light chain include the first arm having
the VH
CA 03089722 2020-07-27
34
presented by the above-mentioned (5b) and the VL of the common light chain
(preferably, the
VL having the VL-CDR1 comprising the amino acid sequence set forth in SEQ ID
No. 26, the
VL-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 27 and the
VL-CDR3
comprising the amino acid sequence set forth in SEQ ID No. 28), and further
the first arm
having the VH comprising the amino acid sequence set forth in SEQ ID Nos. 5
and the VL of
the common light chain (preferably, the VL comprising the amino acid sequence
set forth in
SEQ ID No. 25).
[0049]
Herein, preferable examples of the "first arm specifically binding to PD-1" of
the
present invention include the first arm having the VH presented by any one
selected from the
above-mentioned (lb) to (5b). Furthermore, as mentioned above, the preferable
first arm
also includes those in which 1 to 5 arbitrary amino acid residues are
substituted with other
amino acid(s) (preferably, conservative amino acid(s) thereof) in each CDR of
the VH, and
the substitution with the amino acid(s) does not substantially affect the
binding activity to
PD-1. Furthermore, as mentioned above, the preferable first arm includes those
having the
VH in which the amino acid sequences of frameworks are encoded by the germ-
line V gene
IGHV7-4-1 or the J gene JH6c or gene(s) thereof with somatic mutation(s).
Then, more
preferable examples of the first arm include those having the VH comprising
the amino acid
sequence set forth in any one selected from SEQ ID Nos. 1 to 5.
[0050]
Furthermore, the first arm specifically binding to PD-1 of the present
invention
preferably a common light chain, and preferable examples of such a common
light chain
include a light chain encoded by the IGVK1-39/JK1 common light chain. More
preferable
examples include the light chain containing a VL having the CDR1 comprising
the amino acid
sequence set forth in SEQ ID No. 26, the CDR2 comprising the amino acid
sequence set forth
in SEQ ID No. 27, and the CDR3 comprising the amino acid sequence set forth in
SEQ ID No.
28, and further preferable examples include the light chain containing the VL
comprising the
amino acid sequence set forth in SEQ ID No. 25. Furthermore, preferable
examples of the
constant region of the common light chain include the light chain constant
region comprising
the amino acid sequence set forth in SEQ ID No. 29.
[0051]
Furthermore, preferable examples of the "first arm specifically binding to PD-
1,"
include those which allows the interaction between PD-1 and PD-L1, interaction
between
CA 03089722 2020-07-27
=
PD-1 and PD-L2, or both of those interactions. Herein, the sentence "allows an
interaction
between PD-1 and PD-L1, interaction between PD-1 and PD-L2, or both of those
interactions" means that even when there is the PD-1/CD3 bispecific antibody
of the present
invention at a 20-fold excess over the concentration of the soluble form PD-Li
or PD-L2, the
5
interaction between PD-Ll and PD-1, interaction between PD-L2 and PD-1, or
both of those
interactions are maintained 50% or more, preferably 70% or more, and more
preferably 80%
or more, compared with those when there is no PD-1/CD3 bispecific antibody of
the present
invention. Furthermore, the definition of "allows the interaction between PD-1
and PD-L1,
interaction between PD-1 and PD-L2, or both of those interactions" may have
the same
10
meaning as that of "which does not substantially inhibit the interaction
between PD-1 and
PD-L1, interaction between PD-1 and PD-L2, or both of those interactions."
[0052]
Correspondence relation between each clone of the anti-PD-1 monoclonal
antibody
obtained to construct the PD-1/CD3 bispecific antibody of the present
invention and the VH
15 amino acid sequence thereof and SEQ ID numbers thereof is shown in Fig. 5.
Correspondence relation between each CDR amino acid sequence in VH of each
anti-PD-1
monoclonal antibody clone and SEQ ID number thereof is shown in Fig. 6.
100531
The second arm specifically binding to CD3
20 In the
present specification, the "second arm specifically binding to CD3"
(hereinafter, which may be abbreviated as the "second arm") means an antibody
portion
having at least a VII of an antibody specifically binding to CD3 (hereinafter,
which may be
abbreviated as an "anti-CD3 antibody"), regardless of whether it is contained
in a part of an
antibody or antibody fragment, or exists not as a part but as a single body.
For example,
25 such a
second arm is composed of the VI-I of the anti-CD3 antibody, and a VL of the
common
light chain constituting the same anti-CD3 antibody, and further includes a
Fab part of an
antibody including the VH and VL. Herein, the sentence "specifically binding
to CD3" is
used as the feature that an antibody can directly bind to CD3 with binding
activity of at least 1
x 10-5 M, preferably 1 x 10-7 M, and more preferably more than 1 x 10-9 M
affinity
30
(dissociation constant (Kd value)), and does not substantially bind to the
other protein.
Furthermore, the "antibody" in the "antibody specifically binding to CD3" or
the "anti-CD3
antibody" means a full-length antibody, which is composed of two heavy chains
and two light
chains linked with disulfide bonds, and preferably a monoclonal antibody
thereof.
CA 03089722 2020-07-27
36
[0054]
Herein, examples of the "second arm specifically binding to CD3" include those
containing the VH having: (le) the VH-CDR1 comprising the amino acid sequence
set forth
in SEQ ID No. 37, the VH-CDR2 comprising the amino acid sequence set forth in
SEQ ID No.
38, and the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No.
39.
[0055]
Furthermore, the "second arm specifically binding to CD3" of the present
invention
includes those in which 1 to 5 arbitrary amino acid residues are substituted
with other amino
acid(s) (preferably, conservative amino acid(s) thereof) in each CDR of the VH
in the
above-mentioned (1c), and which have substantially the same binding activity
to CD3 as that
of the original second arm without any substitutions with the same amino
acid(s). For
example, as to the CDR1, one amino acid residue is substituted with a
conservative amino
acid thereof. As to the CDR2 or the CDR3, one or two amino acid residues
is/are substituted
with conservative amino acid(s) thereof, respectively. Herein, the sentence
"which have
substantially the same binding activity to CD3 as that of the original second
arm without any
substitutions with the same amino acid(s)" mentioned above means that the
binding activity to
CD3 of the second arm substituted with the amino acid is 95% or more,
preferably 98% or
more, and more preferably 99% or more to that of the original second arm
without any
substitutions with the same amino acid(s). Note here that examples of the
"substitution with
conservative amino acid(s)" in each VH-CDR of the second arm include those of
the amino
acid substitution in the first arm mentioned above.
[0056]
Furthermore, the "second arm specifically binding to CD3" in the present
invention
also includes those containing the VH having each CDR comprising the specific
amino acid
sequence mentioned above and in which the FR amino acid sequences of the VH
are encoded
by a specific germ-line gene or gene thereof with somatic mutation(s). For
example, the VH
of the above-mentioned (1c) is encoded by the VDJ recombinant gene in which
the germ-line
V gene is IGHV3-33 or gene thereof with somatic mutation(s). Herein, the amino
acid
sequence encoded by the V gene IGHV3-33 of the germ line (SEQ ID No. 22) is
shown in Fig.
3.
[0057]
Furthermore, the "second arm specifically binding to CD3" of the present
invention
also those which contain each CDR having the above-mentioned specific amino
acid
CA 03089722 2020-07-27
=
37
sequence, and in which the amino acid sequences of the FRs in the VH is
encoded by a
specific germ-line gene or gene thereof with somatic mutation(s). Examples of
such a
second arm include those having the VH comprising the amino acid sequence set
forth in SEQ
ID No. 36.
[0058]
Furthermore, examples of such a "second arm specifically binding to CD3"
include
those which have a VH comprising an amino acid sequence having at least 80%,
preferably at
least 90%, more preferably at least 95%, further more preferably at least 98%,
and still further
preferably at least 99% identity to the amino acid sequence set forth in SEQ
ID No. 36, and in
which the difference from the VH amino acid sequence of the original second
arm has no
substantial effect on the binding activity to CD3 (hereinafter, may be
abbreviated as a
"homologous second arm"). Herein, the sentence "the difference from the VH
amino acid
sequence of the original second arm has no substantial effect on the binding
activity to CD3"
means that the binding activity of the homologous second arm to CD3 is 95% or
more,
preferably 98% or more, and more preferably 99% or more to the binding
activity of the
original second arm.
[0059]
In a yet another embodiment, the "second arm specifically binding to CD3" of
the
present invention includes those containing a variable region of the anti-CD3
antibody (herein,
the variable region includes the VH and VL constituting it.) cross-competing
for (1) the
binding to CD3 with the second arm having the VH presented by the above-
mentioned (1c) or
the VH comprising the amino acid sequence set forth in SEQ ID No. 36 and the
VL of the
common light chain, or (2) the binding to CD3 with the variable region of the
monoclonal
antibody specifically binding to CD3 having the same VH and VL. Herein, the
"cross-competing for the binding to CD3" means that it inhibits the binding of
the second arm
to CD3, regardless of the degree thereof, by binding to the epitope which is
the same as or
partially overlaps with the second arm exemplified in the present
specification. Herein, the
cross-competition can be similarly evaluated by the same method as described
about the "first
arm specifically binding to PD-1".
[0060]
Herein, preferable examples of the "second arm specifically binding to CD3" of
the
present invention include the second arm having the VH presented by the above-
mentioned
(1c). Furthermore, as mentioned above, preferable examples of the second arm
also include
CA 03089722 2020-07-27
38
those in which 1 to 5 arbitrary amino acid residue(s) is/are substituted with
other amino
acid(s) (preferably, conservative amino acid(s) thereof) in each CDR of the
VH, and the
substitution with amino acid does not substantially affect the binding
activity to CD3.
Furthermore, as mentioned above, preferable examples of the second arm include
those
having the VH in which the amino acid sequences of frameworks are encoded by
the
germ-line gene IGHV3-33 or gene thereof with somatic mutation(s). Then, more
preferable
examples of the second arm include those having the VH comprising the amino
acid sequence
set forth in SEQ ID No. 36.
[0061]
Hereinafter, correspondence relations between the anti-CD3 antibody clones to
construct the PD-1/CD3 bispecific antibodies of the present invention, VH
amino acid
sequences thereof, and SEQ ID numbers thereof are shown in Fig. 7,
respectively.
Correspondence relations between the CDR amino acid sequences in the VH of the
anti-CD3
antibody clones and SEQ ID numbers thereof are shown in Fig. 8, respectively.
[0062]
The "second arm specifically binding to CD3" of the present invention
preferably
contains common light chains, and preferable examples of such a common light
chain include
the IGVK1-39/JK1 common light chain. More preferable examples include a light
chain
containing a VL having the CDR1 comprising the amino acid sequence set forth
in SEQ ID
No. 26, the CDR2 comprising the amino acid sequence set forth in SEQ ID No.
27, and the
CDR3 comprising the amino acid sequence set forth in SEQ ID No. 28, and
further preferable
examples include the light chain containing the VL comprising the amino acid
sequence set
forth in SEQ ID No. 25. Furthermore, preferable examples of the constant
region of the
common light chain include the light chain constant region comprising the
amino acid
sequence set forth in SEQ ID No. 29.
[0063]
Preferable examples of the "second arm specifically binding to CD3" of the
present
invention include a second arm specifically binding to CD3e.
[0064]
Examples of a preferable isotype of the PD-1/CD3 bispecific antibody of the
present
invention include an IgG antibody, further preferably an IgGi antibody or an
IgG4 antibody,
and more preferably an IgGi antibody.
[0065]
CA 03089722 2020-07-27
39
On the other hand, a preferable embodiment of the PD-1/CD3 bispecific antibody
of
the present invention is, e.g., the PD-1/CD3 bispecific antibody,
wherein the first arm specifically binding to PD-1 contains:
(A) the VH in which 1 to 5 arbitrary amino acid residue(s) may be substituted
with other
amino acid(s) (preferably, conservative amino acid(s) thereof) in any one or
more of the
CDR(s) selected from the VH-CDR1, VH-CDR2 and VH-CDR3 in the VH presented by
any
one selected from the above-mentioned (1a) to (4a) or (lb) to (5b); and
(B) the VL of common light chain having the CDR1 comprising the amino acid
sequence set
forth in SEQ ID No. 26, the CDR2 comprising the amino acid sequence set forth
in SEQ ID
No. 27, and the CDR3 comprising the amino acid sequence set forth in SEQ ID
No. 28; and
wherein the second arm specifically binding to CD3 contains:
(C) the VH in which 1 to 5 arbitrary amino acid residue(s) may be substituted
with other
amino acid(s) (preferably, conservative amino acid(s) thereof) in any one or
more of the
CDR(s) selected from the VH-CDR1, VH-CDR2 and VH-CDR3 in the VH presented by
the
above mentioned (1c); and
(D) the VL of common light chain having the CDR1 comprising the amino acid
sequence set
forth in SEQ ID No. 26, the CDR2 comprising the amino acid sequence set forth
in SEQ ID
No. 27, and the CDR3 comprising the amino acid sequence set forth in SEQ ID
No. 28.
[0066]
A more preferable embodiment of the PD-1/CD3 bispecific antibody of the
present
invention is, e.g., the PD-1/CD3 bispecific antibody,
wherein the first arm specifically binding to PD-1 contains:
(A) the VH presented by any one selected from the above (la) to (4a) or (1 b)
to (5b),
and
(B) the VL of common light chain having the CDR1 comprising the amino acid
sequence set
forth in SEQ ID No. 26, the CDR2 comprising the amino acid sequence set forth
in SEQ ID
No. 27, and the CDR3 comprising the amino acid sequence set forth in SEQ ID
No. 28; and
wherein the second arm specifically binding-to CD3 contains:
(C) the VH presented by the above (1c); and
(D) the VL of common light chain having the CDR1 comprising the amino acid
sequence set
forth in SEQ ID No. 26, the CDR2 comprising the amino acid sequence set forth
in SEQ ID
No. 27, and the CDR3 comprising the amino acid sequence set forth in SEQ ID
No. 28.
[0067]
CA 03089722 2020-07-27
,
Furthermore, another preferable embodiment the PD-1/CD3 bispecific antibody of
the present invention is, e.g., the PD-1/CD3 bispecific antibody,
wherein the first arm specifically binding to PD-1 contains:
(A) the VH comprising the amino acid sequence set forth in any one selected
from SEQ ID
5 Nos. 1 to 5, or a VH comprising an amino acid sequence having at least
80% identity to the
amino acid sequence of the same VH; and
(B) the VL of common light chain comprising the amino acid sequence set forth
in SEQ ID
No. 25; and
wherein the second arm specifically binding to CD3 contains,
10 (C) the VH comprising the amino acid sequence set forth in SEQ ID No. 36,
or a VH
comprising an amino acid sequence having an identity of at least 80% to the
amino acid
sequence of the same VH; and
(D) the VL of common light chain comprising the amino acid sequence set forth
in SEQ ID
No. 25.
15 [0068]
The other embodiments more preferably include, e.g., the PD-1/CD3 bispecific
antibody,
wherein the first arm specifically binding to PD-1 contains:
(A) the VH comprising the amino acid sequence set forth in any one selected
from SEQ ID
20 Nos. Ito 5; and
(B) the VL of common light chain comprising the amino acid sequence set forth
in SEQ ID
No. 25; and
wherein the second arm specifically binding to CD3 contains:
(C) the VH comprising the amino acid sequence set forth in SEQ ID No. 36,; and
25 (D) the VL of common light chain comprising the amino acid sequence set
forth in SEQ ID
No. 25.
[0069]
In the PD-1/CD3 bispecific antibody of the present invention, in case that the
antibody is an IgGi antibody, the IgGi antibody in which leucine at position
235 according to
30 the EU numbering system is substituted with glycine, and/or glycine at
position 236 according
to the EU numbering system is substituted with arginine on two heavy chain
constant regions
or a hinge region is preferable. Furthermore, a bispecific antibody in which a
C-terminal
amino acid of heavy chain, e.g., lysine at position 447 according to the EU
numbering system
CA 03089722 2020-07-27
t "
41
has been deleted is preferable. Furthermore, in case that the PD-1/CD3
bispecific antibody
is an IgG4 antibody, an antibody in which serine located in a hinge region and
at position 228
according to the EU numbering system is substituted with proline is
preferable.
[0070]
Furthermore, the preferable embodiment in case that the PD-1/CD3 bispecific
antibody is the IgGI antibody include those in which in a constant region of
the heavy chain
having the VH of the first arm specifically binding to PD-1, leucine at
position 351 according
to the EU numbering system is substituted with lysine and threonine at
position 366 is
substituted with lysine, and in a constant region of the heavy chain having
the VH of the
second arm specifically binding to CD3, leucine at position 351 is substituted
with aspartic
acid and leucine at position 368 is substituted with glutamic acid.
Furthermore, the IgGi
antibody in which in a constant region of the heavy chain having the VH of the
first arm
specifically binding to PD-1, leucine at position 351 according to the EU
numbering system is
substituted with aspartic acid and leucine at position 368 is substituted with
glutamic acid,
and in a constant region of the heavy chain having the VH of the second arm
specifically
binding to CD3, leucine at position 351 is substituted with lysine and
threonine at position
366 is substituted with lysine is also preferable.
[0071]
Examples of the preferable embodiment of the PD-1/CD3 bispecific IgGI antibody
in
which all of the above-mentioned amino acid substitutions in the heavy chain
constant region
are taken include those in which the heavy chain having the VH of the first
arm specifically
binding to PD-1 contains the heavy chain constant region comprising the amino
acid sequence
set forth in SEQ ID No. 23, and the heavy chain having the VH of the second
arm specifically
binding to CD3 contains the heavy chain constant region comprising the amino
acid sequence
set forth in SEQ ID No. 24. Those amino acid sequences are shown in Fig. 9.
[0072]
The most preferable embodiments of the PD-1/CD3 bispecific antibody of the
present invention are the PD1-1(Bi) clone, PD1-2(Bi) clone, PD1-3(Bi) clone,
PD1-4(Bi)
clone and PD1-5(Bi) clone generated by the method described in Example 8 of
the present
specification.
[0073]
Preferable features of the PD-1/CD3 bispecific antibody of the present
invention
include: (1) allowing the interaction between PD-1 and PD-L1, interaction
between PD-1 and
CA 03089722 2020-07-27
,
42
PD-L2, or both of the interactions; and/or (2) sufficiently reducing cytokine
production.
Herein, the sentence "allowing the interaction between PD-1 and PD-L1,
interaction between
PD-1 and PD-L2, or both of the interactions" means the same as that described
about the
"first arm specifically binding to PD-1." On the other hand, the sentence
"sufficiently
reducing cytokine production" means that, e.g., during intravenous
administration or in 24
hours after that administration, by drip infusion of the PD-1/CD3 bispecific
antibody of the
present invention, e.g., concentration of cytokine containing IL-2, IFN-1
and/or TNF-a in
blood or tissue do not increase, or increase to only such a degree that it can
be suppressed by
steroid administration.
f0074
Method for producing and purifying the PD-1/CD3 bispecific antibody
The PD-1/CD3 bispecific antibody and antibody fragment thereof of the present
invention can also be manufactured by the method disclosed in W02014/051433,
W02013/157953 or W02013/157954.
[0075]
Specifically, the PD-1/CD3 bispecific antibody and antibody fragment thereof
of the
present invention can be manufactured by gene-transferring an expression
vector into which
(1) a polynucleotide encoding the heavy chain containing the VH of the first
arm specifically
binding to PD-1, (2) a polynucleotide encoding the heavy chain containing the
VH of the
second arm specifically binding to CD3, and (3) a polynucleotide encoding the
common light
chain have been inserted, respectively, into mammalian animal cells to
transform them, and
then by having them express and secrete both of the heavy chain and common
light chain.
[0076]
Herein, any host cells for expressing the PD-1/CD3 bispecific antibody of the
present
invention can be used as long as they can be gene-transferred using an
expression vector and
allow the transferred expression vector to express. The host cells are
preferably insect cells
such as SF-9 and SF-21, more preferably mammalian cells such as mouse cells
such as CHO
cells, BHK cells, SP2/0 cells and NS-0 myeloma cells, primate cells such as
COS and Vero
cells, MDCK cells, BRL 3A cells, hybridoma, tumor cells, immortalized primary
cells, W138,
HepG2, HeLa, HEK293, HT1080 or embryonic retina cells such as PER.C6. Note
here that
in selection of the expression system, expression vectors for and hosts as
mammalian host
cells may be used to ensure that an antibody is appropriately glycosylated.
Human cell lines,
preferably PER.C6 are advantageously used to obtain an antibody of which
glycosylated
CA 03089722 2020-07-27
A
*4
43
patterns correspond to those for human.
[0077]
Protein production in host cells transformed by gene-transfer of expression
vectors
can be carried out with reference to, e.g., Current Protocols in Protein
Science (1995),
Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield PT, ISBN 0-471-11184-8,
Bendig, 1988. Furthermore, general guidelines, procedures and practical
methods to
maximize the productivity of host cell culture can be carried out with
reference to Mammalian
Cell Biotechnology: a Practical Approach (M. Butler, ed., IRL Press, 1991).
Expression of
antibodies in host cells is described in, e.g., publication such as EP0120694,
EP0314161,
EP0481790, EP0523949, US4816567, W02000/63403, and the like.
[0078]
Herein, culture conditions of host cells can be optimized by a well-known
method,
and thereby protein production can be optimized. Examples of culture include,
batch culture,
feeding culture, continuous culture, and hollow-fiber culture in a petri dish,
roller bottle, or
reaction chamber. In order to produce recombinant protein by cell culture in a
large scale
and continuously, it is preferable that cells are proliferated in suspension
liquid. Furthermore,
it is more preferable that cells are cultured in a condition without animal-
or human-derived
serum or some components in animal- or human-derived serum.
[0079]
An antibody expressed in host cells and then recovered from cells or cell
culture by
well-known methods can be purified using well-known methods. Examples of the
purification method include an immunoprecipitation method, centrifugation
method, filtration,
size-exclusion chromatography, affinity chromatography, cation and/or anion
exchange
chromatography, hydrophobic interaction chromatography, and the like.
Furthermore,
protein A or protein G affinity chromatography may be preferably used (see,
e.g., US4801687
and US5151504).
100801
Anti-PD-1 monoclonal antibody
The present invention includes a "monoclonal antibody specifically binding to
PD-1"
(hereinafter, may be abbreviated as an "anti-PD-1 monoclonal antibody") to
construct the
PD-1/CD3 bispecific antibody of the present invention and antibody fragment
thereof.
[0081]
One embodiment of the anti-PD-1 monoclonal antibody of the present invention
is a
CA 03089722 2020-07-27
" =
44
monoclonal antibody capable of specifically binding to PD-1 by association of
a VH and the
VL of the common light chain of the present invention. Herein, the sentence
"specifically
binding to PD-1" is used as a feature that it can directly bind to PD-1 with
binding activity
(dissociation constant (Kd value)) of at least 1 x 10-5 M, preferably 1 x 1 0
M, and more
preferably more than 1x109M affinity, and does not substantially bind to
receptor members
belonging to a so-called CD28 family receptor, e.g., CD28, CTLA-4 and ICOS.
Herein, an
"antibody" in the "monoclonal antibody specifically binding to PD-1" or the
"anti-PD-1
antibody" means a full-length antibody composed of two heavy chains and two
light chains
linked with disulfide bonds. Furthermore, a "fragment of the monoclonal
antibody
specifically binding to PD-1" is a part of the full-length antibody, and an
antibody including at
least an antigen binding part, and examples of which include Fab, Fab', Fv,
scFv, F(ab1)2, and
the like.
[0082]
Examples of the anti-PD-1 monoclonal antibody of the present invention include
those having any one of the VH selected from the above (I a) to (4a) or (lb)
to (5b)
constituting the VH of the "first arm specifically binding to PD-1" or the VH
comprising the
amino acid sequence set forth in any one selected from SEQ ID Nos. 1 to 5, and
the VL of
common light chain of the present specification.
[0083]
Furthermore, the anti-PD-1 monoclonal antibody of the present invention
includes
those in which 1 to 5 arbitrary amino acid residue(s) is/are substituted with
other amino
acid(s) (preferably, conservative amino acid(s) thereof) in each CDR of any
one of the VH
selected from the above-mentioned (la) to (4a) or (lb) to (5b), and which have
substantially
the same binding activity to PD-1 as that of the anti-PD-1 monoclonal antibody
having the
original VH without any substitutions with the same amino acid(s). For
example, as to the
CDR1, one amino acid residue is substituted with a conservative amino acid
thereof. As to
the CDR2 or the CDR3, one or two amino acid residue(s) is/are substituted with
conservative
amino acids thereof, respectively. Herein, the sentence "which have
substantially the same
binding activity to PD-1 as that of the anti-PD-1 monoclonal antibody having
the original VII
without any substitutions with the same amino acid(s)" means that the binding
activity to
PD-1 of anti-PD-1 monoclonal antibody substituted with the amino acid(s) is
95% or more,
preferably 98% or more, and more preferably 99% or more to that of anti-PD-1
monoclonal
antibody having the original VII without any substitutions with the same amino
acid(s).
CA 03089722 2020-07-27
I 0' =
[0084]
Furthermore, examples of the anti-PD-1 monoclonal antibody of the present
invention include those which contain a VH having each CDR comprising the
specific amino
acid sequence mentioned above, and in which the framework amino acid sequences
of the VH
5 is encoded by a specific germ-line gene or gene thereof with somatic
mutation(s), and
examples of which include a specific VH encoded by the specific germ-line gene
or gene
thereof with somatic mutation(s), as described about the above-mentioned
"first arm
specifically binding to PD-1."
[0085]
10 Furthermore, in the anti-PD-1 monoclonal antibodies of the present
invention,
examples of those which have a VH containing each CDR in any one of the VH
selected from
the above (la) to (4a) or (lb) to (5b), and in which the FR amino acid
sequences are encoded
by a specific germ-line gene or gene thereof with somatic mutation(s) include
those having
the VH comprising the amino acid sequence set forth in any one selected from
SEQ ID Nos. 1
15 to 5. Furthermore, examples of such an anti-PD-1 monoclonal antibody
include those
having a VH amino acid sequence having at least 80%, preferably at least 90%,
more
preferably at least 95%, further preferably at least 98%, further more
preferably at least 99%
identity to the amino acid sequence set forth in any one selected from SEQ ID
Nos. 1 to 5,
and having the binding activity to PD-1 that is substantially the same as that
of an anti-PD-1
20 monoclonal antibody having the original VH. Herein, the sentence "having
the binding
activity to PD-1 that is substantially the same as that of an anti-PD-1
monoclonal antibody
having the original VH" means that it has 95% or more, preferably 98% or more,
and more
preferably 99% or more of the binding activity to PD-1 to that of the anti-PD-
1 monoclonal
antibody having the original VH.
25 [0086]
Furthermore, other embodiments of the anti-PD-1 monoclonal antibody of the
present invention also include an anti-PD-1 monoclonal antibody cross-
competing for the
binding to PD-1 with an anti-PD-1 monoclonal antibody having any one of the VH
selected
from the above-mentioned (1 a) to (4a) or (lb) to (5b) or the VH amino acid
sequence set forth
30 in any one selected from SEQ ID Nos. 1 to 5, and an anti-PD-1
monoclonal antibody with
which the binding to PD-1 is cross-competed by an anti-PD-1 monoclonal
antibody having
any one of the VH selected from the above-mentioned (la) to (4a) or (lb) to
(5b) or the VH
comprising the amino acid sequence set forth in any one selected from SEQ ID
Nos. 1 to 5.
CA 03089722 2020-07-27
=
1
46
[0087]
Preferable features of the anti-PD-1 monoclonal antibody of the present
invention
include allowing the interaction between PD-1 and PD-L1, interaction between
PD-1 and
PD-L2, or both of the interactions, as well as the PD-1/CD3 bispecific
antibody of the present
invention.
[00881
Polynucleotide encoding a PD-1/CD3 bispecific antibody
A polynucleotide encoding the PD-1/CD3 bispecific antibody comprises: (1) a
polynucleotide encoding the heavy chain having the VH of the first arm
specifically binding
to PD-1, (2) a polynucleotide encoding the heavy chain having the VH of the
second arm
specifically binding to CD3, and (3) polynucleotides encoding the common light
chains.
Herein, the polynucleotide encoding the heavy chain having the VH of the first
arm
specifically binding to PD-1 comprises a polynucleotide encoding the VH of the
first arm
specifically binding to PD-1 and a polynucleotide encoding a constant region
of the heavy
chain having the VH. Similarly, a polynucleotide encoding the heavy chain
having the VH
of the second arm specifically binding to CD3 comprises a polynucleotide
encoding the VH
of the second arm specifically binding to CD3 and a polynucleotide encoding a
constant
region of the heavy chain having the VH.
[0089]
The polynucleotide encoding the PD-1/CD3 bispecific antibody may be any
polynucleotides as long as they encode each of parts constituting the PD-1/CD3
bispecific
antibody, and may be any of genome DNA, cDNA, synthesis DNA, RNA, and DNA-RNA
hybrid. As a codon encoding one amino acid, one to six types of codons are
known. For
example, Phe corresponds to TTT or TTC, Leu corresponds to TTA, TTG, CTT, CTC,
CTA or
CTG, Ile corresponds to ATT, ATC or ATA, Met correspond to ATG, Val
corresponds to GTT,
GTC, GTA or GTG, Ser corresponds to TCT, TCC, TCA or TCQ Pro corresponds to
CCT,
CCC, CCA or CCG, Thr corresponds to ACT, ACC, ACA or ACG, Ala corresponds to
GCT,
GCC, GCA or GCG, Tyr corresponds to TAT or TAC, His corresponds to CAT or CAC,
Gin
corresponds to CAA or CAG, Asn corresponds to AAT or AAC, Lys corresponds to
AAA or
AAG, Asp corresponds to GAT or GAC, Glu corresponds to GAA or GAG, Cys
corresponds
to TGT or TGC, Trp corresponds to TGG, Arg corresponds to CGT, CGC, CGA or
CGG, Ser
corresponds to AGT or AGC, Arg corresponds to AGA or AGG, and Gly corresponds
to GGT,
GGC, GGA or GGG, respectively. Accordingly, the polynucleotide encoding the PD-
1/CD3
CA 03089722 2020-07-27
47
bispecific antibody includes polynucleotides in which codons corresponding to
each amino
acid are arbitrarily combined. Preferable examples of the polynucleotide
encoding the VH
of the first arm specifically binding to PD-1 include a polynucleotide having
the base
sequence set forth in any one selected from SEQ ID Nos. 30 to 34 encoding the
VHs of the
PD1-1 to PD1-5 clones, respectively. Preferable examples of the polynucleotide
encoding
the VH of the second arm specifically binding to CD3 include a polynucleotide
having the
base sequence set forth in SEQ ID No. 40. Furthermore, preferable examples of
the
polynucleotide encoding a variable region of the common light chain include a
polypeptide
having the base sequence set forth in SEQ ID No. 35.
f00901
Pharmaceutical use
The PD-1/CD3 bispecific antibody of the present invention is useful for
preventing,
suppressing symptom progression or recurrence of, and/or treating autoimmune
diseases or
graft-versus-host diseases (GVHD).
[0091]
Examples of diseases which can be prevented, of which symptom progression or
recurrence can be suppressed, and/or which can be treated by the PD-1/CD3
bispecific
antibody of the present invention include Behcet's disease, systemic lupus
erythematosus,
chronic discoid lupus erythematosus, multiple sclerosis (systemic scleroderma,
and
progressive systemic sclerosis), scleroderma, polymyositis, dermatomyositis,
periarteritis
nodosa (polyarteritis nodosa, and microscopic polyangiitis), aortitis syndrome
(Takayasu's
arteritis), malignant rheumatoid arthritis, rheumatoid arthritis, juvenile
idiopathic arthritis,
spondyloarthritis, mixed connective tissue disease, Sjogren's syndrome, adult
Still's disease,
vasculitis, allergic granulomatous vasculitis, hypersensitivity vasculitis,
rheumatoid vasculitis,
large vessel vasculitis, ANCA associated vasculitis (e.g., granulomatosis with
polyangiitis and
eosinophilic granulomatosis with polyangiitis), Cogan's syndrome, RS3PE,
temporal arteritis,
polymyalgia rheumatica, fibromyalgia, antiphospholipid antibody syndrome,
eosinophilic
fasciitis, IgG4-related disease (e.g., primary sclerosing cholangitis,
autoimmune insulitis),
Guillain-Barre syndrome, myasthenia gravis, chronic atrophic gastritis,
autoimmune hepatitis,
non-alcoholic steatohepatitis, primary biliary cirrhosis, Goodpasture's
syndrome, rapidly
progressive glomerulonephritis, megaloblastic anemia, autoimmune hemolytic
anemia,
pernicious anemia, autoimmune neutropenia, idiopathic thrombocytopenic
purpura, Basedow
disease (Graves' disease (hyperthyroidism)), Hashimoto disease, autoimmune
adrenal
CA 03089722 2020-07-27
1
48
insufficiency, primary hypothyroidism, Addison's disease (chronic
hypoadrenocorticism),
idiopathic Addison's disease, type I diabetes mellitus, slowly progressive
type I diabetes
mellitus (latent autoimmune diabetes in adult), focal scleroderma, psoriasis,
psoriatic arthritis,
bullous pemphigoid, pemphigus, pemphigoid, gestational herpes, linear IgA
bullous
dermatosis, acquired epidermolysis bullosa, alopecia areata, vitiligo,
vitiligo vulgaris,
neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy,
multifocal motor
neuropathy, sarcoidosis, giant cell arteritis, amyotrophic lateral sclerosis,
Harada disease,
autoimmune optic neuropathy, idiopathic azoospermia, habitual abortion,
inflammatory bowel
disease (e.g., ulcerous colitis, and Crohn's disease), celiac disease,
ankylosing spondylitis,
severe asthma, chronic urticarial, transplantation immunity, familial
mediterranean fever,
eosinophilic chronic rhinosinusitis, dilated cardiomyopathy, systemic
mastocytosis, or
inclusion body myositis.
[0092]
In the present invention, the term "treatment" means cure or improvement of a
disease or symptom thereof. The term of "prevention" means that the onset of a
disease or
symptom thereof is prevented or delayed for a certain period. The term
"suppression of
symptom progression" means that the progress or deterioration of symptoms is
suppressed to
stop the progress of disease conditions. The meaning of "prevention" includes
suppression
of recurrence. The term "suppression of recurrence" means that the recurrence
of certain
disease or syndrome is prevented or a possibility of recurrence is reduced.
[0093]
The PD-1/CD3 bispecific antibody of the present invention is usually
administered
systemically or locally through parenteral administration. Specific examples
of such
administration methods include injection administration, intranasal
administration,
transpulmonary administration, percutaneous administration, or the like.
Examples of
injection administration include intravenous injection, intramuscular
injection, and
intraperitoneal injection. For intravenous injection, drip intravenous
infusion is preferable.
The dose thereof varies depending on the age, body weight, symptoms,
therapeutic effect,
administration method, treating period, and the like. The single dose thereof
for one adult
patient is usually within a range of 0.1 1.i.g/kg to 300 mg/kg and
particularly preferably within
a range of 0.1 mg/kg to 10 mg/kg, once to several times per day by parenteral
administration,
or within a range of one hour to 24 hours per day by intravenous sustaining
administration.
Needless to say, as mentioned above, since the dose varies depending on
various conditions,
CA 03089722 2020-07-27
49
the sufficient dose may be lower than the above-mentioned dose, or
administration more than
the above may be needed.
(00941
Formulation
When the PD-1/CD3 bispecific antibody of the present invention is formulated
to be
used as an injection or infusion solution for drip infusion, the injection or
infusion solution
may be in any form of an aqueous solution, suspension, or emulsion, or may be
formulated as
a solid agent together with pharmaceutically acceptable carrier such that that
agent will be
dissolved, suspended, or emulsified in a solvent at the time of use. Examples
of the solvent
that is used in the injection or the infusion solution for drip infusion
include distilled water for
injection, physiological saline, glucose solutions, and isotonic solutions
(e.g., in which
sodium chloride, potassium chloride, glycerin, mannitol, sorbitol, boric acid,
borax, propylene
glycol or the like is soluble.).
[0095]
Herein, examples of the pharmaceutically acceptable carriers include
stabilizers,
solubilizers, suspending agents, emulsifiers, soothing agents, buffering
agents, preservatives,
antiseptic agents, pH adjusters, and antioxidants. As the stabilizers, various
amino acids,
albumin, globulin, gelatin, mannitol, glucose, dextran, ethylene glycol,
propylene glycol,
polyethylene glycol, ascorbic acid, sodium bisuffite, sodium thiosulfate,
sodium edetate,
sodium citrate, dibutylhydroxytoluene, or the like can be used. As the
solubilizers, alcohols
(e.g., ethanol), polyols (e.g., propylene glycol, polyethylene glycol and the
like), nonionic
surfactants (e.g., Polysorbate 20 (registered trademark), Polysorbate 80
(registered trademark),
HCO-50 and the like), or the like can be used. As the suspending agents,
glyceryl
monostearate, aluminum monostearate, methyl cellulose, carboxymethyl
cellulose,
hydroxyrnethyl cellulose, sodium lauryl sulfate or the like can be used. As
the emulsifiers,
gum arabic, sodium alginate, tragacanth, or the like can be used. As the
soothing agents,
benzyl alcohol, chlorobutanol, sorbitol, or the like can be used. As the
buffering agents,
phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate
buffer, Tris buffer,
glutamic acid buffer, epsilon aminocaproic acid buffer, or the like can be
used. As the
preservatives, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl
parahydroxybenzoate, butyl parahydroxybenzoate, chlorobutanol, benzyl alcohol,
benzalkonium chloride, sodium dehydroacetate, sodium edeate, boric acid,
borax, or the like
can be used. As the antiseptic agents, benzalkonium chloride,
parahydroxybenzoic acid,
CA 03089722 2020-07-27
3 11
chlorobutanol, or the like can be used. As the pH adjusters, hydrochloric
acid, sodium
hydroxide, phosphoric acid, acetic acid, or the like can be used. As the
antioxidants, (1)
aqueous antioxidants such as ascorbic acid, cysteine hydrochloride, sodium
bisulfate, sodium
metabisulfite, and sodium sulfite, (2) oil-soluble antioxidants such as
ascorbyl palmitate,
5 butylated hydroxy anisole, butylated hydroxy toluene, lecithin, propyl
gallate, and
a-tocopherol, and (3) metal chelating agents such as citric acid,
ethylenediaminetetraacetic
acid, sorbitol, tartaric acid, and phosphoric acid, or the like can be used.
[0096]
The injection or infusion solution for drip infusion can be produced by
performing
10 sterilization in the final process, or aseptic manipulation, e.g.,
performing sterilization by
filtration with a filter or the like, and subsequently filling an aseptic
container. The injection
or infusion solution for drip infusion may be used by dissolving the vacuum
dried or
lyophilized aseptic powder (which may include a pharmaceutically acceptable
carrier powder)
in an appropriate solvent at the time of use.
15 [00971
Combination use or combination formulation
Furthermore, the PD-1/CD3 bispecific antibody of the present invention may be
used
in combination with other agent that is used for preventing, suppressing
symptom progression,
or recurrence of, and/or treating autoimmune disease. In the present
invention, examples of
20 administration form in such combination use with the other agents
(combination use) may
include a form of combination formulation containing both ingredients in one
formulation, or
a form being administered in separate formulations. Such combination use can
supplement
the preventive, symptom progress-suppressive, recurrence-suppressive, and/or
therapeutic
effect of the other agent, or can maintain or reduce the dose or frequency of
administration of
25 the other agent. In the present invention, in a case of separately
administering the PD-1/CD3
bispecific antibody and the other agent, the both agents may be simultaneously
administered
for a certain period of time, and then only the PD-1/CD3 bispecific antibody
or the other
agent may be administered. Alternatively, the PD-1/CD3 bispecific antibody of
the present
invention may be firstly administered, and after the completion of the
administration, the
30 other agent may be administered. The other agent may be firstly
administered, and then the
PD-1/CD3 bispecific antibody of the present invention may be administered. The
administration method may be the same as or different from each other. The
present
invention also can provide a kit containing a formulation containing the PD-
1/CD3 bispecific
CA 03089722 2020-07-27
AI
1
51
antibody of the present invention and a formulation containing the other
agent. The dose of
the other agent can be appropriately selected based on the dose in clinical
use. The other
agent may be a combination of two or more kinds of arbitrary agents at an
appropriate ratio.
Examples of the other agent include not only those already known but also
those newly
discovered in the future.
[0098]
For example, when the PD-1/CD3 bispecific antibody of the present invention is
applied to prevention, suppression of symptom progression or recurrence and/or
treatment of
type I diabetes mellitus, it may be used in combination with, e.g., any one or
more of agent(s)
selected from an. insulin preparation (e.g., human insulin, insulin glargine,
insulin lispro,
insulin detemir, insulin aspart, and the like.), sulfonylurea agent (e.g..,
glibenclamide,
gliclazide, or glimepiride), quick-acting insulin secretion promoter (e.g.,
nateglinide),
biguanide preparation (e.g., metformin), insulin resistance improving agent
(e.g.,
pioglitazone), a-glucosidase inhibitor (e.g., acarbose, voglibose, and the
like.), diabetic
neuropathy therapeutic agent (e.g., epalrestat, mexiletine, imidapril, and the
like.), GLP-1
analog preparation (e.g., liraglutide, exenatide, lixisenatide, and the
like.), and DPP-4
inhibitor (e.g., sitagliptin, vildagliptin, alogliptin, and the like.), and
the like.
[0099]
Furthermore, for example, when the PD-1/CD3 bispecific antibody of the present
invention is applied to prevention, suppression of symptom progression or
recurrence and/or
treatment of multiple sclerosis, it may be used in combination with any one or
more of
agent(s) selected from a steroid agent (e.g., cortisone acetate,
hydrocortisone, hydrocortisone
sodium phosphate, hydrocortisone sodium succinate, fludrocortisone acetate,
prednisolone,
prednisolone acetate, prednisolone sodium succinate, prednisolone
butylacetate, prednisolone
sodium phosphate, halopredone acetate, methylprednisolone, methylprednisolone
acetate,
methylprednisolone sodium succinate, triamsinolone, triamsinolone acetate,
triamsinolone
acetonide, dexamethasone, dexamethasone acetate, dexamethasone sodium
phosphate,
dexamethasone palmitate, paramethasone acetate, or betatnethasone), interferon
13-1a,
interferon 0-lb, glatiramer acetate, mitoxantrone, azathioprine,
cyclophosphamide,
cyclosporin, methotrexate, cladribine, adrenocorticotropic hormone (ACTH),
corticotropin,
mizoribine, tacrolimus, fingolimod, or alemtuzumab, and the like.
[0100]
Furthermore, for example, when the PD-1/CD3 bispecific antibody of the present
CA 03089722 2020-07-27
52
invention is applied to prevention, suppression of symptom progression or
recurrence and/or
treatment of systemic lupus erythematosus, it may be used in combination with
any one or
more of agent(s) selected from a steroid agent (e.g., steroid agents mentioned
above),
immunosuppressive agent (e.g., cyclosporin, tacrolimus, or fingolimod), and
belimumab.
[0101]
For example, when the PD-1/CD3 bispecific antibody of the present invention is
applied to prevention, suppression of symptom progression or recurrence and/or
treatment of
rheumatoid arthritis, it may be used in combination with any one or more of
agent(s) selected
from a steroid agent (e.g., the steroid agents mentioned above), anti-
rheumatic agent (e.g.,
methotrexate, sulfasalazine, bucillamine, leflunomide, mizoribine, tacrolimus,
and the like.),
anti-cytokine agent (e.g., infliximab, adalimumab, tocilizumab, etanercept,
golimtunab,
sertolizumab, and the like.), and abatacept, and the like.
[0102]
In the case of applying the PD-1/CD3 bispecific antibody of the present
invention to
prevention, suppression of symptom progression or recurrence and/or treatment
of other
autoimmune diseases, the PD-1/CD3 bispecific antibody of the present invention
may be used
in combination with any one or more of the above-mentioned other agent(s).
[0103]
The present invention will now be described in more detail by the following
examples, but the scope of the present invention is not limited thereto. A
person skilled in
the art can make various changes and modifications, based on the description
of the present
invention, and such changes and modifications are also included in the present
invention.
Examples
[01041
Example 1: Immunization of MeMo mice using recombinant human PD-1-Fe fusion
nrotein
As a method for obtaining the first arm specifically binding to PD-1 of the
present
invention, a method for immunizing MeMo mice (see W02009/157771) with a
recombinant
human PD-1 protein is selected. The MeMo mice are those genetically modified
such that a
gene fragment including a non-recombinant human heavy chain V gene region, D
gene region,
and J gene region as well as a recombinant human lc light chain IgVic1-
39*01/IGhd*01
germ-line gene is linked to a mouse constant region gene. By directly
immunizing the
MeMo mice with a target protein of an antibody, antibodies composed of heavy
chains and
common light chains, with diversity, can be produced.
CA 03089722 2020-07-27
t
53
[0105]
Twelve 12- to 16-week-old MeMo MS5B/MS9 mice were immunized with
recombinant human PD-1-Fc fusion protein (R&D Systems, serial number 1086-PD)
which
had been emulsified using Gerbu adjuvant MM (Gerbu Biotechnik, serial number
#3001) at
an interval of 14 days. On days 0, 14 and 28 after immunization, the
recombinant human
PD-1-Fc fusion protein was subcutaneously administered. At timing later than
that, the
recombinant human PD-1-Fe fusion protein dissolved in PBS was subcutaneously
administered. On days 21, 35, 56, 77 and 98 after immunization, the antibody
titer in serum
was evaluated by flow cytometry using a human PD-1 forced-expressed HEK293 T
cell lines.
When the human PD-1 forced-expressed HEK293T cell lines were stained in 1000-
fold
diluted serum, mouse lymph tissue of which MFI value was not less than three
times higher
than that of the human PD- I non-expressing HEK293T cell lines as a control
was used for
constructing a phage display library. Mice satisfying the criteria for
constructing the library
construct were additionally immunized with the recombinant PD-1-Fc fusion
protein for three
days from the evaluation date of the antibody titer, and of which the spleens
and inguinal
lymph nodes were collected. Mice in which the antibody titer in serum to human
PD-1 and
cynomolgus monkey PD-1 was 1/100 or more, and the antibody titer was not
increased by
additional immunization were also subjected to the same method, and then of
which the
spleens and inguinal lymph nodes were collected. RNA was extracted from those
lymphoid
tissues, and then cDNA synthesis was carried out.
101061
Example 2: Construction of phage display library for obtaining anti-PD-1
antibody having the
first arm specifically binding to PD-1 (protein immunization)
PCR reaction was carried out using DNA prepared in Example 1 and primers
specific
to inununoglobulin heavy chain variable region family. The obtained PCR
product was
digested with restriction enzymes SfiII and XhoI, and inserted into MV1473
phagemid vector
[having a gene (human x light chain IgVx1-39*01/IGJO*01 germ-line gene)
encoding the
common light chain] digested with the same restriction enzymes to construct
the library.
1-0107]
Example 3: Screening of anti-PD-1 antibody having the first arm specifically
binding to PD-1
Phage selection based on the binding property to PD-1 was carried out using
plates
coated with human PD-1-Fe fusion protein, human PD-1-His tag fusion protein,
cynomolgus
monkey PD-1-His tag fusion protein or mouse PD-1-His tag fusion protein. When
using the
CA 03089722 2020-07-27
=
r.4
54
human PD-1-Fe fusion protein, during incubation with phage, human IgG (SIGMA,
serial
number 14506) was added to absorb Fe reactive clones. The binding phages which
can bind
to human PD-1, cynomolgus monkey PD-1 and mouse PD-1 were enriched. The phages
which can bind to cynomolgus monkey PD-1 were enriched by using selections on
cynomolgus monkey PD-1 expressing HEK293 T cell lines. Escherichia coli strain
TG1
clones transformed with phages obtained by selection were obtained to produce
a master
plate.
[0108]
Furthermore, based on the binding property to PD-1 on a plate coated with
human
PD-1-Fe fusion protein, phage selection was carried out using a periplasmic
space extract of
the clones obtained by the above-mentioned selection. Note here that as the
criteria for
selection, clones with signals three times more than that (01)450 value)
obtained from negative
control wells (PBS) were defined as positive clones.
f0109j
Example 4: DNA sequence for anti-PD-1 antibody candidate clones having the
first arm
specifically binding to PD-1
DNA sequence for a heavy chain variable region gene of positive clones
obtained by
screening in Example 3 was carried out. Analyzed DNA sequences were classified
into
super clusters (a group having the same length CDR3, and an amino acid
sequence of CDR3
is 70% or more homologous) and clusters (a group in which amino acid sequences
of the
heavy chain CDR3 are the same). Nine hundred and twenty-four clones were
obtained,
which were classified into 146 types super clusters and 194 types clusters.
101101
Example 5: Screening based on binding property evaluation to PD-1 expressing
cells
From each of the classified super clusters, anti-PD-1 monoclonal antibody
clones
satisfying the following conditions were screened to isolate them:
(1) somatic mutation(s) was/were introduced into CDR region(s) with high
frequency;
(2) a germ-line gene of VH with high frequency in use was included, and
(3) a high signal was obtained in the binding property screening to human PD-1-
Fe fusion
protein.
[0111]
The evaluation was carried out by detecting the binding to human PD-1-
expressing
CHO-S cell lines and cynomolgus monkey PD-1-expressing CHO-S cell lines with
an
CA 03089722 2020-07-27
I
anti-mouse IgG polyclonal antibody, using Fab fragments contained in these
periplasmic
space extracts. Among the evaluated 117 clones (105 types of clusters), It was
recognized
that 22 clones including anti-PD-1 monoclonal antibody PD1-1, PD1-2, PD1-3 and
PD1-4
clones can bind to the human PD-1 expressing CHO-S cell lines.
5 101121
Example 6: Production of an amino acid substituted product of anti-PD-1
monoclonal
antibody having the first arm specifically binding to PD-1
The PD1-1 and PD1-4 clone include a deamidation motif (Asn-Gly) in the
framework 4 of the heavy chain variable region, respectively. In order to
obtain the first arm
10 with reduced risk of deamidation, a variant in which the deamidation motif
has been
converted was produced. The PD1-5 clone was produced such that asparagine
(Asn) at
position 119 according to the EIJ numbering system of the PD1-4 clone was
altered to
glutamine by a well-known site-specific mutation method, which was isolated.
The binding
property to human PD-1 expressing CHO-S cells of that clone was equal to that
of the PD1-4
15 clone.
101131
Example 7: Screening of anti-CD3 monoclonal antibodies having the second arm
specifically
binding to CD3
In order to obtain a Fab binding to CD3 having more stability and further
reduced
20 charge heterogeneity, an anti-CD3 antibody having the "second arm
specifically binding to
CD3" of the present invention was obtained by the following method, using the
anti-CD3
antibody clone having the VH of the anti-CD3 antibody 15C3 clone described in
W02005/118635 and IGVK1-39/JK1 common light chain.
[0114]
25 By converting the underlined 55th glycine in the VH amino acid
sequence of 15C3
shown in Fig. 10, into alanine, the anti-CD3 antibody CD3-1 clone, having the
binding
property to human CD3 equal to that clone and having improved charge
heterogeneity was
obtained.
[0115]
30 Furthermore, in order to obtain a plurality of Fabs binding to CD3 to
improve the
VH/VL interaction with the common light chain (IgVic1-39*01/IGJK1*01) based on
the VH
of the CD3-1 clone, a phage display library expressing a plurality of Fabs
including VH
variants of CD3-1 clone in which that amino acid residue has been substituted
was
CA 03089722 2020-07-27
1
56
constructed. This phage library was subjected to screening using HBP-ALL cells
or
recombinant human CD3c-Fc protein. A phages binding to the recombinant human
CD3c-Fc protein were chemically eluted, and used for reinfection to bacteria.
A plurality of
survived bacterial colony were extracted, then phages therefrom were
extracted, and then
screened by flow cytometry, based on the binding to CD3 expressed on cell
surface. All of
the phages binding to CD3 were subjected to colony PCR to amplify cDNA
encoding its VH,
and DNA sequences thereof were determined.
[0116]
As a result, the obtained anti-CD3 antibody CD3-2 clone having the VH
comprising
the amino acid sequence set forth in SEQ ID No. 36 showed the binding property
to CD3 and
charge homogeneity equivalent to those of the CD3-1 clone.
101171
Example 8: Preparation of the PD-1/CD3 bispecific monoclonal antibody
An expression vector expressing each heavy chain of the first arm specifically
binding to PD-1 was produced by linking DNAs encoding heavy chain variable
regions of the
anti-PD-1 monoclonal antibody PD1-1 to PD1-5 and PD1-6 clones, respectively,
selected in
Example 5, to DNAs encoding Igth heavy chain constant regions, respectively.
On the other
hand, an expression vector expressing a heavy chain of the second arm
specifically binding to
CD3 was produced by linking a DNA encoding a heavy chain variable region of
the anti-CD3
monoclonal antibody CD3-2 clone selected in Example 7 to a DNA encoding an
Igth heavy
chain constant region. Herein, as genes expressing such heavy chain constant
regions, as to
the first arm specifically binding to PD-1, a gene expressing an Fe region
having
L351D/L368E variation (DE variation) was used. As to the second arm
specifically binding
to CD3, a gene expressing an Fe region having L351K/T366K variation (KK
variation) was
used. These expression vectors were constructed so as to further include a
gene encoding
the IGVK1-39/JK1 common light chain such that it will be expressed together.
Furthermore,
genes expressing these heavy chain constant regions have been modified to
express those in
which leucine at position 235 was substituted with glycine and further glycine
at position 236
was substituted with arginine in the heavy chain constant region, in order to
eliminate the Fe
effector activity, and further lysine at a position 447 at C-terminal of the
heavy chain constant
region was deleted, in order to avoid processing after translation, were used.
Both of these
expression vectors were gene-transferred into Free Style 293F cell to produce
antibodies in
culture supernatants. The culture supernatants were collected and then treated
by protein A
CA 03089722 2020-07-27
57
affinity chromatography, to purify the PD1-1(Bi) clone, the PD1-2(Bi) clone,
the PD1-3(Bi)
clone, the PD1-4(Bi) clone, and the PD1-5(Bi) clone of the PD-1/CD3 bispecific
monoclonal
antibody of the present invention, respectively. Furthermore, the PD1-6(Bi)
clone was also
produced by the same method. Note here that, in that these PD-1/CD3 bispecific
monoclonal antibody clones have the first arms specifically binding to PD-1
derived from the
anti-PD-1 monoclonal antibody: PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 clones,
as well as
PD1-6 clone, used in production thereof, they correspond to those anti-PD-1
monoclonal
antibody clones, respectively.
101181
Example 9: Evaluation of the binding property of the PD-1/CD3 bispecific
monoclonal
antibody
By Biacore assay using human IgGl-Fc fused human PD-1 extracellular
recombinant
protein or 6xHis tag fused cynomolgus monkey PD-1 extracellular recombinant
protein, the
binding affinities to each PD-1 recombinant protein of the first arms of the
PD-1/CD3
bispecific monoclonal antibodies obtained in Example 8 were evaluated. Note
here that for
immobilization of the recombinant proteins, Series S Sensor Chip CM5 Sensor
Chip (GE
Health Care, serial number 29-1049-88) was used. Similarly, by the Biacore
assay using a
human IgG1 -Fc fused CD38/CD3e extracellular recombinant protein, the binding
affinities to
CD3 of the second arms of the antibodies were evaluated. Fig. 11 shows the
binding affinity
(Kd value) to PD-1 of the first arm and the binding affinity to CD38/CD3E of
the second arm
with respect to each clone.
J01191
Example 10: Verification of the binding property of the PD-1/CD3 bispecific
monoclonal
antibody
It was verified that the PD-1/CD3 bispecific monoclonal antibodies obtained in
Example 8 specifically can bind to PD-1 and CD3, simultaneously.
[0120]
Firstly, the PD1-1(Bi) to PD1-6(Bi) clones were added to human PD-1 deficient
Jurkat cell lines (human T cell line) expressing human CD3, respectively, and
which were
incubated on ice for 15 minutes. After those cells were washed, soluble PD-1
recombinant
proteins (R&D systems, serial number 1086-PD-050) labeled with 3-fold amount
of biotin
were added, and incubated on ice for 15 minutes. After those cells were
washed, 100 )1i, of
1.25 pig/mL Alexa Fluor 488-labeled streptavidin (BioLegend, serial number
405235) was
CA 03089722 2020-07-27
58
added to them, and which were incubated on ice for 15 minutes. After those
cells were
washed, a binding amount of the soluble PD-1 recombinant protein was evaluated
by flow
cytometry. Fig. 12 shows results of the assay.
[0121]
All of the clones bound to PD-1 and CD3 simultaneously. Note here that
nonspecific binding in this binding system was not detected.
[0122j
Example 11: Evaluation of the binding property of the first arm of the PD-
1/CD3 bispecific
monoclonal antibody
In order to evaluate effects on the PD-1/PD-L1 binding of the first arms of
the
PD-1/CD3 bispecific monoclonal antibodies obtained in Example 8, a competitive
binding
assay with respect to the binding to PD-1 of the bispecific monoclonal
antibody clones and
soluble PD-Li recombinant proteins was carried out. Firstly, the PD1-1(Bi) to
PD1-6(Bi)
clones were added to human PD-1 expressing CHO-S cell lines, respectively, and
which were
incubated on ice for 30 minutes. The soluble PD-Li recombinant proteins (R&D
systems,
serial number 156-B7-100) labeled with 1/20 amount of biotin were added to
them, and which
were incubated on ice for 30 minutes. After those cells were washed, PE-
labeled
streptavidin (BD Pharmingen, serial number 554061) was added to them, and
which were
incubated on ice for 30 minutes. After those cells were washed, a binding
amount of the
soluble PD-Ll recombinant proteins was evaluated by flow cytometry. Fig. 13
shows its
results of the assay.
[0123]
Although there are the clones PD1-1(Bi) to PD1-5(Bi) at the amount of 20 times
more than that of the soluble PD-Llrecombinant protein, they allowed the
soluble PD-L1
recombinant protein to bind to PD-1. On the other hand, PD1-6(Bi) completely
inhibited the
binding to PD-1 of the soluble PD-L1 recombinant protein in the same
conditions.
101241
Example 12: In vitro suppressive effects of the PD-1/CD3 bispecific monoclonal
antibody on
activated CD4 T cells
Suppressive effects of activated T cells on IFNI production were evaluated
using
CD4 positive T cells derived from healthy human peripheral blood (LONZA,
serial number
2W-200) (human T cells). Human T cells were seeded on a cell culture plate on
which
anti-human TCRV[38 antibodies (Thermo Scientific, serial number TCR1750) have
been
CA 03089722 2020-07-27
I
59
solid-phased, anti-human CD28 antibodies (BioLegend, serial number 302923)
were added
thereto, and subjected to activation treatment for 72 hours. Next, the human T
cells that
have been subjected to activation treatment were cultured overnight in a fresh
medium
containing 100 Units/mL human IL-2 (R&D systems, serial number 202-IL).
Furthermore,
the collected human T cells were seeded on another cell culture plate on which
anti-human
TCRVI38 antibodies have been solid-phased, and anti-human CD28 antibodies were
added
thereto, as well, and then activation treatment was carried out again. At this
time, the
PD1-1(Bi) to PD1-6(Bi) clones were added thereto, respectively, and then IFN-7
contained in
the culture supernatant 96 hours after the reactivation treatment was
quantified by ELISA
(pg/mL). Fig. 14 shows its results. Suppressive activities of IFNI production
of the
PD1-1(Bi) to PD1-5(Bi) clones were confirmed. Suppressive activity of IFN-7
production
of the PD1-6(Bi) clone trends to decrease more than other clones. An antibody
obtained by
immunization of tetanus toxoid by the same technique as that to obtain the
first arm, which is
a non-specific antibody, was used as a control antibody.
[01251
Example 13: In vivo effects of the PD-1/CD3 bispecific monoclonal antibody on
experimental
allergic encephalomyelitis mouse model (EAE model)
In vivo effects of the PD-1/CD3 bispecific monoclonal antibody of the present
invention were evaluated in an EAE model using a human CD3e/human PD-1 knock-
in
C57BL/6 mice in which CDR gene and PD-1 gene have been substituted with human
CD3s
gene and human PD-1 gene, respectively. Killed mycobacterium tuberculosis
H37Ra (BD
Biosciences, serial number 231141) and incomplete Freund's adjuvant (BD
Biosciences, serial
number 263910) were mixed with each other to prepare a complete Freund's
adjuvant (CFA)
containing 4 mg/mL killed mycobacterium tuberculosis H37Ra. 1 mg/mL MOG
peptide
(ANASPEC, serial number AS-60130) and the equal amount of CFA were mixed with
each
other to prepare a emulsion as an eliciting agent of the EAE model. The 200
eliciting
agents were subcutaneously administered to tail head of the C57BL/6 mice. On
the
treatment day of the immunization and on day 2, 200 pL of 1 p,g/mL of
pertussis toxin
(SIGMA-ALDRICH, serial number P7208) were administered in tail vein,
respectively.
Next, on day 6 and 7 of immunization, 2 mg/kg of the PD1-1 (Bi) to PD1-6 (Bi)
clones were
intraperitoneally administered to the C57BL/6 mice once a day, respectively.
The
neurological symptoms after the immunization were evaluated in accordance with
the method
of Onuki, et al. (Onuki M,et al., Microsc Res Tech 2001; 52: 731-9). The
degrees of
CA 03089722 2020-07-27
= 4'4 1
neurological symptoms were scored (normal: score 0, tail relaxation: score 1,
hind limb
partial paralysis: score 2, hind limb paralysis: score 3, forelimb paralysis:
score 4, and dying
or death: score 5). If a plurality of neurological symptoms were observed, the
higher score
was employed as the neurological symptom on the evaluation day. The
neurological
5 symptom of died mice was scored to 5 until completion of the
observation. Figs. 15 to 17
show its evaluation results. Note here that the human CD3e/human PD-1 knock-in
C57BL/6
mice were produced by mating the human CD3e knock-in mouse produced, according
to the
method described in Genesis. 2009 Jun; 47(6): 414-22, with the human PD-1
knock-in mouse
by a well-known method.
10 [0126]
In the EAE model, the onset of the neurological symptoms was remarkably
suppressed with respect to any of the PD1-1 to PD1-5(Bi) clones, but
significant suppressive
effect was not observed with respect to the PD1-6(Bi) clone.
101271
15 Example 14: Evaluation of in vitro effect of PD-1/CD3 bispecific
monoclonal antibody on
cytokine release from human peripheral blood monocyte
For the purpose of analyzing the cytokine releasing activity of the PD-1/CD3
bispecific monoclonal antibody, the experiment in which the PD-1/CD3
bispecific
monoclonal antibody clones of the present invention or the PD-1/CD3 bispecific
scDb
20 (J110xUCHT1) disclosed in Patent Literature 2 are added to human peripheral
blood
mononuclear cells (hereinafter, referred to as "human PBMC") was carried out.
Each clone
of the PD-1/CD3 bispecific monoclonal antibodies and J110xUCHT1 were added to
human
PBMC (LONZA, serial number CC-2702) such that their concentrations were 30
pg/mL and
10 pg/mL, respectively, and then which were cultured for 24 hours. After
culture for 24
25 hours, each IL-2 contained in their culture supernatants was quantified by
multiplex
immunoassay (BIO-RAD, serial number M50000007A). Fig. 18 shows its results.
Note
here that the amount of IL-2 production (pg/mL) in the figure are presented by
mean value
standard error (N = 3).
[0128]
30 J110xUCHT1 remarkably induced IL-2 production. However, IL-2
productions
with respect to any clone of the PD-1/CD3 bispecific monoclonal antibodies
were low.
[01291
Example 15: Evaluation of cross-competitive activity for binding to PD-1 of
each clone of the
CA 03089722 2020-07-27
" =
61
PD-1/CD3 bispecific monoclonal antibodies with the PD1-5(Bi)
Cross-competition assay was conducted to evaluate cross-competitive activity
for
binding to PD-1 of each PD1-1(Bi) to PD1-5(Bi) clones of the PD-1/CD3
bispecific
monoclonal antibody, obtained in Example 8, with the PD1-5(Bi).
[0130]
At first, the PD1-5(Bi) clone was added to human PD-1-expressing CHO-S line
cells,
then which were incubated on ice for twenty minutes. Further, one-hundredth
amount of the
biotin-labeled clones PD1-1(Bi) to PD1-5(Bi) compared to that of the already-
added
PD1-5(Bi) clone were added to those cells, respectively, then which were
incubated on ice for
20 minutes. Those cells were washed, to which PE-labeled streptavidin (BD
Phanningen,
model number 554061) was added, and then were incubated on ice for 20 minutes.
After
washing those cells, the binding amount of the biotin-labeled clones PD1-1(Bi)
to PD1-5(Bi)
were measured using flow cytometry. Figure 19 shows that result.
[0131]
It was demonstrated that the PD1-5(Bi) clone can inhibit each binding to PD-1
of the
PD1-1(Bi) to PD1-5(Bi) clones, and thus that the PD1-5(Bi) clone can cross-
compete with
their binding to PD-1.
Industrial Applicability
[0132]
The PD-1/CD3 bispecific antibody or an antibody fragment thereof of the
present
invention is useful for preventing, suppressing symptom progression or
recurrence of, and/or
treating autoitnmune diseases or graft-versus-host diseases (GVHD).
Sequence Listing
